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The liver is the only human internal organ capable of regeneration. It is indispensable to 
most metabolic functions, such as bile production, metabolism of lipids, carbohydrates, 
proteins and amino acids, and breakdown of hormones. Since almost all other organs in 
the body rely on the liver for their smooth functioning, it is not surprising that the liver 
is closely related to a plethora of diseases. Liver failure, cholestasis and sepsis are 
common liver related disorders. A major drawback related to current biomarkers for 
liver disorders, such as aspartate aminotransferase (AST), gamma-glutamyl transferase 
(GGT) and interleukins, is that they have limited diagnostic accuracy and specificity. 
Therefore, there is an urgent need to investigate metabolites that associate with different 
liver conditions, which can then potentially be utilised as biomarkers and therapeutic 
targets. The focus of my thesis was to apply metabolomics on human and mouse liver 
tissues to further understand its biochemistry under stress and facilitate the discovery of 
potential endogenous biomarkers under those conditions. 
Chapter two involved an in-depth analysis of metabolic variations in two main types of 
liver donor tissues. Lipid fingerprints in 112 matched pre- and post-transplant liver 
biopsies from donation after circulatory death (DCD, n=36) and donation after brain 
death (DBD, n=76) were investigated using Reversed Phase-Mass Spectrometry (RP-
MS). Two lysophosphatidylcholines, LysoPC (16:0) and LysoPC (18:0), showed 
higher levels in DCD, before transplantation (q < 0.01). These findings imply that the 
two LysoPCs play a role in perpetrating tissue damage induced by warm ischaemia. 
Interestingly, elevated amounts of these two lipids were also observed in recipients 
undergoing early allograft dysfunction (EAD) (p < 0.05). 
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After comparing DBD and DCD groups and identifying two potential lipid biomarkers 
of EAD, we decided to target lipids that are known to induce inflammation since 
ischaemia reperfusion injury (IRI) is associated with the release of pro-inflammatory 
mediators. In Chapter 3, a targeted analysis of five ceramides was carried out in 46 (10 
DBD, 13 DCD) paired biopsies at both transplantation stages. It was found that C18, 
C20, C24 ceramides showed significant differences in DBD (p<0.05) pre- and post-
transplantation, while C22 ceramide (p<0.05) showed more pronounced changes in the 
DCD group. A strong correlation between levels of C18 ceramide and bilirubin and 
creatinine, two common markers of liver dysfunction, suggested the involvement of C18 
ceramide with IRI in DCD. 
In Chapter 4, we aimed to extend the lipidomics results and investigated more polar 
molecules. Hydrophilic interaction chromatography-MS (HILIC-MS) analysis was 
performed on 35 DBD and 12 DCD paired liver samples (n=94). Orthogonal Projections 
to Latent Structures-Discriminant Analysis (OPLS-DA) modelling suggested the 
involvement of five metabolites from the adenosine monophosphate (AMP) pathway. 
Elevated levels of AMP and adenine were indeed found in the DBD group, after 
univariate analysis (p<0.01). These changes were also seen in recipients experiencing 
immediate graft function (IGF) (p<0.05), suggesting that they may contribute to healthy 
allograft function and improve graft survival rate.  
In chapter 5, an animal model of cholestasis was studied. Untargeted lipidomic analysis 
and semi-targeted bile acids analysis were applied to mouse livers (7 controls, 6 
cholestatic) and plasma (8 controls, 10 cholestatic) from a cholestatic model. A panel of 
5 lipids, including 2 phosphatidylcholines (PC (36:3), PC (34:2)) and 3 cholesterol 
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esters (CE (16:0), CE (16:1), CE (18:1)) showed significant differences between 
cholestatic and control mice (p<0.05). In addition, Receiver Operating Characteristic 
(ROC) curve revealed a high potential of these five lipids in discriminating cholestatic 
mice from controls, with area under the curve (AUC) of 100%, when compared to 
plasma enzymes (91.2%) and bile acids (77.5%). 
Lastly, my focus moved to sepsis in order to understand inflammation in the liver and if 
this can affect the brain via the liver-brain axis. Liver and brain samples (4 controls, 6 
septic) from a septic mouse model were analysed with both RP-MS and HILIC-MS 
untargeted approaches. A panel of 9 annotated metabolites, including previously 
discussed LysoPC (16:0), CE (16:0) and CE (18:1), were uncovered through a meta-
analysis which employed three machine learning tools. Subsequently, a correlation 
analysis was performed between this panel of metabolites and general indicators of sepsis. 
Based on all the statistical tools applied, glycerylphosphorylethanolamine; a lipid 
depleted in both liver and brain from septic mice (p<0.05); was selected as the most 
promising candidate biomarker for endothelial dysfunction during sepsis.  
Overall, this work has revealed a panel of key metabolites that are all specifically 
associated with a range of liver related diseases. Through comparing two types of liver 
donation, DBD and DCD, LysoPC (16:0) and LysoPC (18:0) were found to be 
potential biomarkers of liver tissue damage. In the meanwhile, adenine and AMP were 
discovered to be putative biomarkers of allograft function and survival. Furthermore, 
inflammatory lipids, ceramides, were also studied in DBD and DCD groups, diverse 
distributions of five chosen ceramides and correlations with liver dysfunction markers 
were observed. Moving from human studies to mouse experiments, in a cholestasis 
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model, a panel of 5 lipids, including phosphatidylcholines and cholesterol esters, were 
proved to have higher predictive ability compared with traditional enzymes.  In addition, 
glycerylphosphorylethanolamine was chosen as a promising biomarker of endothelial 
dysfunction in a mouse sepsis study involving liver-brain axis. Future work entails 
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1.1 Liver Related Diseases 
Liver related diseases, including  non-alcoholic fatty liver disease (NAFLD), non-
alcoholic steatohepatitis (NASH), cirrhosis, hepatocellular carcinoma (HCC), 
cholangiocarcinoma (CCA), alcoholic liver disease (ALD), hepatitis B and C virus 
(HBV and HCV) infection, sepsis, cholecystitis, cholestasis, liver failure, and drug-
induced hepatotoxicity,  are major cause of illness and death worldwide, affecting at 
least 2 million people in the UK alone [1, 2].  
Among all liver related conditions, hepatic steatosis, or fatty liver, is common in the 
general population [3]. This condition is associated with metabolic syndrome, which is 
characterized by obesity and/or insulin resistance. Exposure to other risk factors, 
particularly alcohol abuse and HCV infection, can also cause steatosis [4]. NAFLD is 
defined as the presence of excessive accumulation of triglycerides in the liver of 
individuals with minimal or no alcohol intake, comprising a variety of diseases, ranging 
from simple steatosis to steatohepatitis (NASH), with or without the development of 
fibrosis and cirrhosis [5]. In addition, viral hepatitis, such as HBV (partly double-
stranded DNA virus) and HCV (single-stranded RNA virus), are affecting more than 
150 million people as a global health challenge. Persistent infection can lead to 
progressive liver disease with the development of liver cirrhosis and HCC [6, 7].  
In the following chapters, three types of liver associated syndromes, liver transplantation, 
cholestasis and sepsis, will be reviewed. Interruption of bile flow may have an 
extrahepatic and obstructive or an intrahepatic and biochemical basis, which causes 




[8]. Patients with sepsis often develop a conjugated hyper-bilirubinaemia, suggesting 
that the secretion of bilirubin into bile is compromised. Moreover, the initiation of 
hepatic injury in septic conditions usually results from decreased hepatic arterial blood 
flow [9]. This can lead to poor hepatic microcirculation, resulting in acute cellular and 
mitochondrial injury, leading to elevated hepatic transaminases, severe hypoglycaemia 
and reduced production of coagulation factors [9]. Liver transplantation is required 





1.2 Liver Transplantation 
The liver is a vital organ for human beings with various functions including 
detoxification and production. Furthermore, it is also the only human internal organ 
capable of natural regeneration of lost tissue; as little as 25% of a liver can regenerate 
into a whole liver [10]. Liver transplantation is performed when the liver has been 
damaged as it loses its normal functional ability. Liver failure can be caused by acute 
and chronic diseases (as seen in Figure 1.1). For acute disease, there are several types, 
like drug-induced toxicity, viral hepatitis, acute budd-chiari syndrome and metabolic 
diseases [11]. Chronic liver diseases include alcoholic-related liver disease (ALD), 
chronic hepatitis B or C, malignancy, non-alcoholic steatohepatitis, autoimmune 


















Figure 1.1. Schematic flow shows the development of liver diseases from a healthy liver with various 
influencing factors (blue boxes). NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic 
steatohepatitis; HCC, hepatocellular carcinoma; HBV, hepatitis B virus; HCV, hepatitis C virus. Figure 




1.2.1 Donor Types 
Nowadays, the most common types of liver transplantation are donation after brain 
death (DBD), donation after circulatory of death (DCD) and more rarely living 
donation (LD). Brain death is a state of cessation of cerebral function, which is 
considered irreversible. A ventilator which allows the blood to continue to circulate 
throughout the body is normally provided to a brain-dead donor. Because of this, the 
organs remain suitable for organ donation [12]. DCD, previously referred to as donation 
after cardiac death or non-heartbeating organ donation, refers to the donor who does 
not meet the criteria for brain death but in whom cardiac standstill or cessation of cardiac 
function occurred before the organs were procured [13]. Living donation transplant is a 
surgical procedure to procure an organ or portion of an organ from a living person and 
place it in another person whose organ is no longer functioning properly. Shortage of 
donors for hepatic transplantation has led to the reintroduction in the last decade of 
DCD, with the hope of increasing the number of viable grafts for transplantation by 10-
20% [14-16]. DBD has  been the dominant source of grafts since the introduction of 
brain stem death criteria (which defines brain death as unresponsiveness and lack of 
receptivity, the absence of movement and breathing, the absence of brain-stem reflexes, 
and coma with known cause) in 1968, due to improved graft quality and the potential 
for multi-organ donation [14, 17, 18]. 
To safeguard patients, pre-transplant donor screening is used to determine the plausible 
success rate of liver transplants. The optimal/sub-optimal criteria for liver donors 
includes age (<50 years/>50 years), weight (<100kg/>100kg), intensive care stay (<5 
days/>5 days), functional warm ischaemic time (<20 mins/>20mins, <30mins), cold 




According to analysis conducted by the Liver Transplant Program team in King’s 
College Hospital London, 4,632 donation offers were received in their unit from 2001 
to 2010. Of 1,579 DCD offers, 621 (39.3%) were accepted for further evaluation and 
958 declined. Of the accepted offers, 400 (64.4%) had experienced circulatory arrest 
after withdrawal of support and their livers were recovered and assessed for graft 
viability. Of these, 183 (45.8%) grafts were transplanted [14]. 
In addition, based on the typical donor recovery procedure for DCD, the majority of 
potential offers are turned down as unsuitable [16]; graft utilization has decreased to 68% 
with the use of DCD, compared with 90.3% for DBD [14]. The number of livers 
recovered at DCD but not applied has increased due to four main reasons: DCD long-
term outcomes, cholangiopathy, organ quality and related graft dysfunction [20].  
DBD donations are widely adopted for liver transplantation, and it is thought to be a 
better organ source compared with DCD donation since there is no preceding 
circulatory arrest. However, brain death generates an inflammatory response with the 
release of various pro-inflammatory mediators, leading to upregulated expression of 
adhesion molecules on vascular endothelium and subsequent leukocyte tissue 
infiltration [21, 22]. The pathophysiology of donor liver grafts sourced from circulatory 
death is evidently different from that of liver grafts sourced from DBD. DCD livers are 
exposed to a period of warm ischaemia, which is understood to be involved in continued 
energy consumption by viable cells at body temperature. Though a circulation exists, 
the organ is still exposed to a hypoxic insult from poor end organ perfusion, which leads 
to cellular damage [23]. This inadequate level of oxygenated blood through tissue 




primary graft failure in DCD grafts [24].  The difference in ischemic injury that DCD 
livers experience in comparison to DBD livers from the time of procurement to donation 
is illustrated in Figure 1.2. 
Traditionally, donor organs are kept in an ice box during transportation. Many potential 
donor organs cannot be utilised because sub-optimal livers do not tolerate conventional 
cold storage and it is challenging to assess organ viability preoperatively [25]. In recent 
years, studies and trials on the application of ex-vivo normothermic machine perfusion 
(NMP) has gained increasing attention worldwide. In practice, following removal from 
the donor, the liver was attached to the NMP device, where it was perfused throughout 
the duration of preservation, until it was removed from the device for implantation [26]. 
Normothermic machine perfusion maintains the liver in a physiological state, averts 
cooling and allows recovery and functional testing when compared with static cold 





Figure 1.2. The phases of ischemic injuries on liver allografts from procurement to donation after 
cardiac death (DCD) versus donation after brain death (DBD). Figure adapted and modified from [27]. 
 
Since the first successful living donor liver transplantation in 1989 [28, 29], LD has been 
accepted in most countries in order to decrease the mortality on the transplantation 
waiting list [30]. Although the ischaemia time involved in LD is the shortest compared 
with most deceased donation, the risk of the surgery for donors should not been 
overlooked [31, 32]. Moreover, components of the transplant evaluation process may 
complicate the donation pairing process. It includes the requirements of donors to have 
matched blood type to help improve the chances that the donor organ will not be 




examination, may be performed to assess the donor’s liver as well as the donor’s overall 
health status. 
 
1.2.2 Organ Allocation 
Rational and unbiased allocation criteria were not an issue when the first liver 
transplantation was performed by Thomas Starzl in 1963 [33]. Transplants were 
restricted to candidate recipients who were lucky enough to be managed at the same 
institution as the deceased donor, as organs had a very short viability period [34].  
Later on, with the acceptance of brain death criteria, donor organ preservation 
techniques and quality were improved, making the allocation of donated livers at other 
sites feasible [35]. At the same time, the increasing demand of transplant organs has 
inflated the waiting lines, this made necessary the development of an impartial and 
structured organ distribution system [34, 36]. The listing system improved from basing 
solely on waiting time to disease severity, and to Child-Turcotte-Pugh score after a 
decade’s  progress from 1990s [37]. Lastly, the Model for End-stage Liver Disease 
(MELD) was adopted in the United States in 2002, and a similar scoring system, 
Paediatric End-stage Liver Disease (PELD), was created for paediatric patients [34, 35]. 
In the United Kingdom, a different system called UKELD score was developed and 
validated with 1000 patients on the waiting list, which includes sodium in addition to 
the MELD score factors (bilirubin, INR of prothrombin time and serum creatinine) [38]. 
Since hyponatremia is related to neurologic dysfunction, higher risk for development of 




was conducted and has been shown to improve the predictive accuracy of the MELD 
score [39].  
 
1.2.3 Ischaemia/Reperfusion Injury  
Liver ischaemia/reperfusion (I/R) injury is the injury caused by the ischaemia and 
reperfusion stages in liver retrieval, transporting and implanting. Liver retrieval involves 
the deprivation of blood and oxygen to the liver, and the livers are cold preserved until 
the time of transplantation with the aim of keeping them viable [40]. Low temperature 
protects tissue by slowing the rate of cell death, while the preservation solutions assists 
to prolong storage time [41].  
The damage is sustained during the cold preservation after liver retrieval and during 
warm reperfusion at implantation in recipients. The reintroduction of host blood supply 
after reperfusion induces the release of active and potentially toxic chemical products 
that can cause damage to organs [42]. Furthermore, reperfusion of allografts involves the 
interaction of host lymphoid cells with the donor innate immune cells, which may affect 
the immune response after transplantation [43].   
In addition, in DCD cases, there is extra warm ischaemia injury before the hepatic cold 
perfusion [44]. It is also considered as the main reason of primary graft dysfunction or 
initial function failure after transplantation, both of which can eventually lead to acute 
and/or chronic rejection [45].  
In ischaemia injury, endothelial cells and hepatocytes are damaged in the process of 




The absence of oxygen during the ischaemic phase leads to interruption of the 
mitochondrial electron transport chain, debacle of adenosine triphosphate production, 
and disturbance of electrolyte homeostasis [48, 49]. For reperfusion injury, the 
formation of reactive oxygen species during the re-oxygenation process stimulates 
oxidative stress and mitochondrial permeability transition (MPT) [50]. The activation 
of Kupfer cells and formation of pro-inflammatory cytokines including tumour necrosis 
factor-α (TNF-α), interleukin-6 (IL-6) and chemokines lead to neutrophil-related 
injury, followed by necrosis [51]. As a result of ischaemia/reperfusion insult, necrosis 
can cause subsequent organ failure [52].   
For allografts from those three main donation categories, there are different extents of 
I/R injury. LD livers are supposed to experience minimal damage compared with 
allografts from the other two types [53]. Due to extra warm ischaemia in DCD and long 
ITU stays for DBD donors, the injury including oxidative stress, inflammation and cell 
death could affect the liver quality and transplantation outcomes to some extent [54]. 
A primary goal of the pre-transplantation donor evaluation is to determine whether the 
donor liver is more susceptible to I/R injury and consequently, whether its use will result 
in graft dysfunction following transplantation [55, 56]. While the assessment is an 
important patient safeguard, it may also result in otherwise transplantable organs being 
discarded. Increasing the pool of available and transplantable livers by identifying new 





1.2.3.1 Oxidative stress 
Free radicals are highly reactive and consequently short-lived molecules formed in cells 
as a response to many exogenous and endogenous factors affecting cellular metabolism 
[59]. The most common ones are oxygen-derived free radicals – hydroxyl radical (*OH), 
superoxide radical (*O2), nitric oxide radical (NO*), and the nonradicals hydrogen 
peroxide (H2O2), referred as reactive oxygen species (ROS) [60]. ROS, easily reacts 
with other molecules in a cell, are generated during various physiological and 
pathological processes [61]. Many diseases are associated with damage from ROS as a 
consequence of an imbalance between radical-generating and radical-scavenging 
systems - a condition called oxidative stress [62]. 
Sources of oxidative stress in liver transplant recipients include I/R injury, 
immunosuppressive treatment, graft dysfunction and pre-transplant conditions [63]. 
ROS are signalling molecules at low concentrations, however, at higher concentrations 
they can harm cellular macromolecules. To prevent this, excessive amount of ROS is 
eliminated through effective enzymatic (eg. superoxide dismutase and glutathione 
pathway) and non-enzymatic pathways (eg. vitamin C, vitamin E and uric acid) [64]. 
In addition, when the defence mechanisms operated by antioxidants are not sufficient, 
released ROS triggers several incidents in hepatocytes, inclusive of accretion of Ca2+, 
production of NO, caspase activation, cytokine gene upregulation, and lipid, protein, 
and DNA damage [65]. If the rate of ROS production exceeds the capacity of 
converting them to chemically inert molecules, it results in oxidative injury to tissue [66]. 
Among the most mentioned modes of injury, lipid peroxidation is thought to be the main 




Although it is impractical to measure free radicals due to their fleeting life time, oxidative 
stress can be assessed by other markers. Lipid peroxidation may be evaluated with 
malondialdehyde (MDA), thiobarbituric acid reactive substances (TBARS), exhaled 
alkanes and plasma oxidizability [67-71]. Determination of oxidative damage to 
proteins is essentially based on measurement of plasma carbonyl, a marker of protein 
degradation [72]. The assessment of DNA damage and antioxidant capacity can also be 
achieved by other tests [73].  
 
1.2.3.2  Inflammatory response 
The inflammatory response induced by ischaemia reperfusion is crucial for liver 
transplantation. A key component of inflammation is the recruitment of inflammatory 
cells, like neutrophils, lymphocytes, and monocytes to the site of stimulus [74]. At the 
site of inflammation, tissue damage and augmented oxidative stress were triggered in 
response to the exposure of chemical mediators, including cytokines and chemokines 
[75]. Interestingly, in liver inflammation, ROS have been shown to exert their effects on 
immune cells, leading to up-regulation of gene transcription and modulation of cytokine 
and chemokine expression [76, 77]. Thus, overexpression of the proinflammatory genes 
and ROS results in a virtuous cycle, where increased oxidative stress and inflammatory 
lesion provoke the pathogenesis of I/R injury [78]. 
Cytokines, like chemokines, interferons, interleukins and lymphokines, which are small 
proteins that play significant roles in cell signalling, are produced by a wide range of 




monokine (cytokines made by monocytes), chemokine (cytokines with chemotactic 
activities), and interleukin (IL, cytokines made by one leukocyte and acting on other 
leukocytes) are the common types of cytokines [80]. There are both pro-inflammatory 
and anti-inflammatory cytokines.  Widely studied pro-inflammatory cytokines such as 
tumor necrosis factor-α (TNF-α), IL-1β, and IL-6 are associated with hepatic tissue 
damage during I/R injury that may lead to graft dysfunction [81-83].  
Except from cytokines, bioactive lipids are also well-known inflammatory 
mediators[84]. In particular, ceramides, sphingosine 1-phosphate, and ceramide 1-
phosphate have been widely implicated in inflammation. The biological functions of 
ceramides include potently inducing cell cycle arrest and apoptosis [85]. Interestingly, 
IL-l and TNF, pro-inflammatory cytokines, also activate the sphingomyelin signalling 
pathway resulting in the generation of ceramides in a spectrum of cell types [86]. 
Furthermore, ceramide functions as an important signal messenger by exerting its 
influence on a number of key signal transduction pathways [87, 88]. The distribution 
and alteration of mostly common ceramides (long fatty acyl chains of 16-28 carbons) in 
mammals can be explored to have a better view of their functions in liver transplantation. 
 
1.2.3.3 Cell death 
Warm and cold hepatic ischaemia followed by reperfusion leads to cell death by 
apoptosis and necrosis (Figure 1.3), which may play a crucial role in reducing organ 




Apoptotic mechanisms are canonically divided into two main pathways [91]. The first 
is the ‘intrinsic’ pathway, or mitochondrial pathway, which is activated by a variety of 
cytotoxic stimuli including I/R [92]. In hepatocytes following the triggering, proteins 
such as members of the Bcl2 family are translocated into the outer mitochondrial 
membrane, thereby enables the release of pro-apoptotic proteins, cytochrome c, 
Smac/Diablo and others, from the intermembrane [49, 93]. Cytochrome c forms a 
complex with apoptosis-activating factor-1, ATP and procaspase 9, where the resultant 
‘apoptosome’ activates the caspase 9 and caspase 3 system [49, 92, 94]. Caspase 3 
activity initiates the execution of the final stages of apoptosis, involving cell shrinkage, 
surface blebbing, internucleosomal DNA hydrolysis, chromatin margination and 
nuclear lobulation [49, 91].  
The second is the ‘extrinsic’ pathways, that involves the activation of receptors such as 
the Fas ligand, TNF-α, and tumor necrosis factor-related apoptosis-inducing ligand 
(TRAIL) receptors [95]. Activation of these receptors leads to their trimerization, which, 
in turn, attracts several death domain-containing proteins such as Fas-associated death 
domain (FADD) and TNF- α receptor-associated death domain (TRADD) to the 
receptor complex [96]. These death-inducing signalling complexes promote binding of 
procaspase-8 and its proteolytic activation to catalytic caspase-8. When sufficient 
caspase-8 is produced, it will activate caspase-3. Caspase-3 acts as the cell’s executioner 
by proteolyzing many cellular proteins [49, 91]. 
Cell death induced by necrosis differs from apoptotic death in several ways. Single dying 
cells shrink rather than swell, which happens in apoptosis, whereas big group of cells are 




characterised by cell swelling with small protrusions named blebs from the plasma 
membrane [46]. In contrast to the programmed nature of apoptosis, necrosis was 
considered to occur by uncontrolled processes that led to the ‘accidental’ death of the 
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Figure 1.3. Mechanisms of cell death including necrosis and apoptosis in ischaemia/reperfusion (I/R). 
Figure modified from [89]. 
 
Specifically, it is known that cell stress mobilizes and activates a group of 
serine/threonine kinases named receptor interacting proteins (RIPs) [98]. In particular, 
RIP1 and RIP3 appear to be functional in coordination as mediators of necrosis [99]. 




through activation of NADPH oxidases, or increased mitochondrial oxidant production 
[100]. 
 
1.2.4 Transplant Outcomes  
The two main objectives of liver transplantation are to prolong survival and improve 
quality of life.  
At present, patient survival rates at 1 and 5 years have reached 90% and 70%, 
respectively [101]. Factors that may influence survival rates rely on donor, recipient, 
perioperative, and postoperative characteristics [102]. Donor parameters that may result 
in poor outcomes include advanced age, high BMI, long length of hospitalisation, use of 
vasopressors, and the presence of infection. Recipient parameters include urgent 
indication, renal dysfunction, and the presence of infection. Perioperative factors 
comprise cold and warm ischaemia time, blood product requirements, and surgical 
difficulties. Finally, postoperative factors involve graft dysfunction, renal dysfunction, 
centre experience, need for mechanical ventilation, and prolonged stay in an intensive 
care unit [102, 103].  
Depending on the severity of graft dysfunction, it ranges from reversible dysfunction 
(recognised as early allograft dysfunction (EAD)) to an irreversible state of dysfunction 
known as primary non- function (PNF) [104, 105]. EAD was defined as the presence 
of one or more of the following defined postoperative laboratory parameters: bilirubin 
≥10mg/dL on day 7, international normalised ratio (INR) ≥1.6 on day 7, and alanine or 




Furthermore, PNF was described as a graft with poor initial function requiring re-
transplantation or leading to death within 7 days after the primary procedure without 
any detectable origin of graft failure [107, 108].  Apart from EAD and PNF, clinical 
outcomes can also be classified as immediate graft function (IGF), with values below the 
cut-off points for EAD [55].  
Nowadays, concerns about survival has lessened with improved surgical success, greater 
attention has been placed on issues that can affect the quality of life among liver 
transplant survivors [109]. The Short Form-36 Health Status Survey (SF-36) has 
become the most frequently used quality of life agency in terms of describing and valuing 
the health status of liver transplant recipients [110]. Specifically, SF-36 contains a 36-
item questionnaire covering eight dimensions, including physical functioning, physical 
role limits, bodily pain, general health, vitality, social functioning, emotional role limits, 
and mental health [111]. Meanwhile, the 6-minute walk distance (6MWD) is also a 
widely applied and standardized measure of functional status and exercise capacity for  
recipients [112]. It measures the distance that survivors are able to walk on a flat, hard 
surface within a 6-minute period at a self-determined speed without supporting 






1.3.1 The Prevalence of Cholestasis 
A major function of the liver is the production and secretion of bile [114]. Cholestasis is 
a condition where the bile flow into the intestine is defective [115]. The causes may be 
intrahepatic or extrahepatic, the latter accounts for 70% of all cholestasis cases [116]. 
Cholestasis is not a primary cause of death. However, it is the cause of considerable 
morbidity, since the effects are profound and widespread. Although the principal effects 
involve the function of the liver and intestine, secondary effects can involve every organ 
system, leading to systemic illness [117]. Cholestasis can occur not only to both women 
and men, but also the old, young, and infants [118]. It is reported that women are more 
affected due to the condition of cholestasis in pregnancy with the incidence rate of 7 per 
1,000 pregnancies [119]. On top of this, new-borns and infants are more susceptible and 
more likely to develop cholestasis as a consequence of immaturity of the liver [120].  
 
1.3.2 The Pathology of Cholestasis 
Cholestasis is the result of imbalance between bile acid uptake and efflux. Anomalous 
hepatic build-up of bile salts provokes disruption of cell membranes and organelles 
leading to necrosis, inflammation, and fibrosis [121]. The mechanisms of cholestasis can 
be broadly classified into intrahepatic (also known as hepatocellular), where there are 
disturbances of bile formation, and extrahepatic (also known as obstructive), where 
impediment to bile flow occurs after it is produced (Figure 1.4) [120]. The typical 




within hepatocytes and canalicular spaces, in association with generalized cholate injury, 
where the most common causes are drug reactions and inflammatory disorders like 
cirrhosis and sepsis [114, 122]. Typical of extrahepatic cholestasis is bile plugging of the 
bile ducts, involving blockage by gallstones, extraluminal compression by a tumor, 
narrowing of bile duct by biliary atresia, primary sclerosing cholangitis and inflammation 





(not making enough bile)
Extrahepatic cholestasis
(physical blocking: BA, 
PSC, gallstone, tumor)
 
Figure 1.4. The causes of cholestasis are divided into two groups: intrahepatic cholestasis (those 
originating within the liver) and extrahepatic cholestasis (those originating outside the liver).  
 
Bile is a highly complex water-based medium containing inorganic ions and many 
classes of organic amphiphiles, the formation of which involves multiple mechanisms 
[115, 124]. The transport of solute including bile salts, lipids, bilirubin, electrolytes and 
organic anions into the canaliculus by specific transporters creates chemical and osmotic 
gradients and promotes water flow by a paracellular pathway [125]. Several of these 




(Table 1.1). The identification of defective transporters in some familial cholestatic 
disorders has led to improved understanding of the molecular mechanisms of human 
cholestasis [126, 127].  
Table 1.1. Transporters involved in primary bile formation. Table adapted and modified from [115]. 
Transporter trivial names(s) Gene code Substrate(s) Defective in 
FIC1 ATP8B1 ? PFIC type 1 
BSEP(sPgp) ABCB11 bile salts PFIC type 2 
MDR3 Pgp (in mouse: Mdr2 Pgp) ABCB4 phosphatidylcholine PFIC type 3 
MDR1 Pgp (in mouse: Mdr1a 
and 1b Pgp) 
ABCB1 amphipathic drugs (neutral and 
cationic 
? 




BCRP (MXR, ABCP) ABCG2 amphipathic drugs ? 
ABCG5 ABCG5 (phytosterols) Sitosterolaemia 
ABCG8 ABCG8 no direct evidence yet  
 
Retained bile salts down-regulate new bile synthesis, which results in a reduction of the 
bile salt pool and reduced enterohepatic recirculation [128]. Furthermore, they induce 
injury to biological membranes throughout the body, where the liver is the most affected 
[129]. To be more specific, the retention of hydrophobic bile salts leads to their invasion 
into membranes, which alters membrane fluidity and function [121]. Bile salt injury of 
hepatocyte membranes is a key amplifier of cholestasis, while the retention of secondary 





1.3.3 Clinical Diagnosis for Cholestasis 
For the diagnosis of cholestasis, the first approach is always the clinical history, which 
often is different in both acute and chronic cholestasis [120]. Jaundice is confined 
predominantly to those with acute cholestasis, which arises as a consequence of elevated 
serum conjugated bilirubin [122]. A thorough drug history is imperative. Any 
medications taken within 6 weeks of presentation may be incriminated and only one 
dose may be sufficient to initiate disease. Having investigated the personal history, the 
family history also is very pertinent, especially in the case of familiar intrahepatic 
cholestasis [131]. On top of this, pale stools and dark urine are common signs of 
cholestasis. Pale stools occur as no bilirubin reaches the gastrointestinal tract and dark 
urine results from reflux of conjugated bilirubin into blood which is excreted in the urine 
[132]. The most obvious physical signs of cholestasis are scratch marks and shiny nails 
secondary to persistent scratching. It is proposed that the increased levels of bile salt 
which accumulate under the skin causes the itch, while the prolonged rubbing and 
repetitive scratching make the nails shiny [133]. Other features such as abdominal pain 
and fever can also appear to cholestatic patients [134].  
Further investigation of cholestasis can be carried out when some symptoms mentioned 
above were present. Typically, the biochemical markers of chronic cholestasis are 
elevated levels of the bile duct enzymes like ALP and/or GGT [135]. Although the 
serum ALP level may be increased in bone disease, gastrointestinal disease, or during 
pregnancy, the GGT level is almost specific to the liver [132]. Increased serum levels of 
these enzymes are caused by the damaging effect of high concentrations of bile acids on 




bilirubin and bile salts are commonly measured parameters as well. As these are retained 
to different extents in various cholestatic disorders, their relative levels are taken as 
reference in assisting diagnosis [116]. On top of this, serum transaminases will also be 
raised in obstructive cholestasis and, to a lesser extent, hepatocellular disease [137]. 
Apart from the laboratory tests, initial imaging should include ultrasonography which 
revolutionised the diagnostic work-up of apparent cholestasis because it could clearly 
distinguish intrahepatic from extrahepatic biliary tract disease [138]. If no dilated ducts 
are seen on ultrasound scan, endoscopic retrograde cholangiography (ERCP), the gold 
standard for visualizing the extrahepatic biliary system while providing insight into the 
cause of the obstruction, can be applied [139]. Besides, percutaneous transhepatic 
cholangiography (PTC) is normally adopted when dilated ducts are observed on 
ultrasound scan [132]. The other imaging technique named magnetic resonance 
cholangiopancreatography (MRCP) is non-invasive which can deliver information 
about the hepatobiliary and pancreatic systems [140]. Moreover, the less technician-
dependent computerised tomography (CT) scan may provide some practical 
information and can complement ultrasonography, particularly in obese individuals 
where the latter may be challenging [141]. Lastly, liver biopsy is the single most useful 
test but it is invasive and the above discussed approaches can be sought before a biopsy 





1.3.4 Consequences of Cholestasis and Treatments 
The most prominent feature of cholestasis is pruritus [115]. The first line of treatment is 
the anion-exchange resin, the best-known being cholestyramine. This agent often gives 
rise to gastrointestinal disorder and is poorly tolerated by some but is effective in 80% 
[120]. The second line of therapy is the antibiotic rifampin which is effective in 50% 
[142, 143]. As a third-line therapy, opioid antagonists, is very effective but may lead to 
chronic pain syndrome when used regularly [144]. 
Hypercholemia, or increased serum bile salt concentration, is a universal consequence 
of cholestasis. Hyperlipidemia where serum cholesterol is elevated due to the impaired 
metabolic degradation and excretion is characteristic of some but not all cholestatic 
diseases [145]. These patients have complex dietary needs, especially where the disease 
is enduring. Whilst the fat intake needs to be diminished, the protein and calorie intake 
needs to be maintained [134]. Hence, careful attention should be paid to prevent fat-
soluble vitamin deficiencies (A, D, E, K). The proper approach to treat both 
complications in cholestatic liver disease is to treat the liver disease itself [120]. 
A well-described peripheral complication of chronic cholestasis is metabolic bone 
disease (osteopenia, osteoporosis and occasionally osteomalacia) [117]. Calcium and 
vitamin D supplementation are the drugs of choices with the addition of 
bisphosphonates when necessary [146]. Nonspecific therapies with hydrophilic bile 
acids, like ursodeoxycholic acid (UDCA) that promote bile flow, make physiologic 
sense [147]. UDCA contributes to improved liver biochemistries, liver histology, and 




chronic cholestasis are unresponsive to treatment and unbearable, liver transplantation 






1.4.1 The Definition and Epidemiology of Sepsis 
The word ‘sepsis’ was initially introduced to depict the diseases as a repercussion of self-
intoxication with damaging products derived from the colon [150]. Sepsis is a complex 
and hard-to-define condition with various interactions with other disorders [151]. The 
developments in defining the spectrum of sepsis syndromes and studying their impact 
on human life can be traced back to 4th century B.C. as illustrated in Figure 1.5 [152]. 
In 1991, sepsis was described by ‘systemic inflammatory response syndrome’ (SIRS), 
which is the mechanism of many acute and chronic diseases caused by non‐microbial 
‘irritating causes’, such as autoimmune, metabolic or physical insults [153]. However, 
this non-specific definition does not adequately depict the nature of sepsis, which is 
caused by insufficiently controlled bacterial, fungal and viral infections manifested by 
impairment or collapse of microcirculation [154]. The collapse, also known as septic 
shock, underlies multiple organ failure and culminating in hypotension that is refractory 
to resuscitation measures. In 2016, the Third International Consensus made the new 
definition for sepsis as ‘life-threatening organ dysfunction caused by a dysregulated host 
response to infection’, and described septic shock as a subset of sepsis in which 
particularly serious circulatory, cellular, and metabolic abnormalities are associated with 
a greater risk of mortality than with sepsis alone [155].  
According to studies conducted worldwide, incidence of sepsis in adults at the 
population level ranged from 22 to 240/100 000; of severe sepsis from 13 to 
300/100 000; and of septic shock 11/100 000 [156-158].  Mortality rates depending on 




and 80% for septic shock [159-162]. Furthermore, it was reported that the prevalence 
of paediatric severe sepsis yields 8.2%, according to a screening conducted on 6,925 
septic children treated in 128 participating paediatric intensive care units (PICUs) 
across 26 countries [163].   
• Hippocratic corpus uses ‘sepsis’ to describe decay of organic matter
• Avicenna uses “blood rot” for disease linked to severe purulent processes
• Semmelweis discovers that practitioner hand washing reduces incidence of puerperal sepsis on maternity ward
• Schottmueller established link between microbes in the blood stream and sepsis
• CDC’s MMWR is the first US national report of increasing discharge for septicaemia 1979-1987
• ACCP/SCCM consensus definition for SIRS and sepsis
• Friedman et al. summarise literature from 1958-1997: Sepsis source changing from 
abdomen to chest 
• Angus et al. publish first administrative definition of severe sepsis using ICD-9-CM codes 
• Martin et al. publish second ICD-9-CM definition of severe sepsis 1979-2000
• First Surviving Sepsis Guidelines: Define SIPS, Sepsis, Severe sepsis 
and Septic shock
• Surviving Sepsis Guideline, Second Edition
• Melamed et al. define first ICD-10 definition for sepsis 
mortality
• Surviving Sepsis Guideline, Third Edition
• The Third International Consensus 
Definitions for Sepsis and Septic Shock 
400s BC 1110s 1847 1914 1990 1991 1998 2001 2003 2004 2008 2009 2012 2016  
Figure 1.5. Abbreviated Timeline of the Conceptual Definition of Sepsis. Figure adapted and modified 
from [152].  
 
1.4.2 The Pathology of Sepsis 
Extensive research has been done to interpret the pathology of sepsis. Although it turns 
out to be rather heterogeneous and intricate, the discovery of involved multiple systems 




It is widely accepted that the host defence, rather than the microorganisms is responsible 
primarily for the morbidity and mortality from sepsis [165]. The damage to our own 
body can be linked with the excessive response of innate immune system. Immune cells 
identify not only invading molecules (pathogen-associated molecular patterns; PAMPs) 
but also injured tissues (damage-associated molecular patterns; DAMPs) [166]. From 
both attacking microorganisms and damaged host tissues, the accumulated DAMPs 
greatly trigger host immune system, which leads to systemic inflammatory response 
syndromes (SIRS), also described as ‘cytokine storm’ [164, 167]. Although the genetic 
deletion or antagonising some of proinflammatory mediators (eg. TNF-α and IL-1) 
improved the survival of septic animals, clinical trials of anti-inflammatory agents did 
not demonstrate any benefit [168, 169]. With the acceptance of ‘cytokine storm’ 
concept, the understanding of sepsis was further enhanced by the discovery of Toll-like 
receptors (TLRs) that are pattern recognition receptors (PRRs) [170]. TLRs recognise 
PAMPs and DAMPs, and stimulate intracellular signalling leading to the production of 
inflammatory cytokines [166]. While target therapy against one well-known TLR in a 
clinical trial showed contrary response to high risk and low risk sepsis patients [171], the 
exploration of other pathophysiological alternation in sepsis is still in progress. 
Adequate recruitment of leukocytes to the sites of infection is one of the early and key 
features of effective immune response [172]. In order to migrate into the sites of infection, 
leukocytes experience steps of rolling on the blood vessels and adhering onto the 
vascular endothelial cells [173]. Adhesion molecules such as selectins, integrins, and 
intercellular adhesion molecules (ICAMs) are among the significant participants [174]. 
In mild local infection, leukocytes are activated and recruited locally at the site of 




recruitment to the original sites of infection is rather decreased [175, 176]. Sepsis models 
tested in majority of knockout mice (various adhesion molecules) revealed worse 
mortalities when compared to wild type mice [177-179], while enhanced or no 
reduction neutrophil recruitments were also observed in some cases [180, 181]. 
Extensive apoptosis of lymphocytes and gastrointestinal epithelial cells was discovered 
though the autopsy study of patients who died from sepsis [182]. Furthermore, animal 
and clinical studies suggested that the initial hyperinflammatory response was quickly 
followed by the development of the sustained anti-inflammatory response [183]. T 
helper 1 (TH1) cells and TH2 cells are a type of T cells that play a crucial role in adaptive 
immune system where they help the activity of other immune cells by releasing T cell 
cytokines [184]. During sepsis, the shift from TH1 response (pro-inflammatory 
cytokines interferon (IFN)γ, IL-12, and TNF-β production) to TH2 response (IL-4, IL-
5, IL-10, and IL-13 production) occurs, leading into significant immunosuppression. 
Hotchiss et al. proposed that the apoptosis of lymphocytes might further worsen this 
trend. Notably, the time frame of death from sepsis mostly coincides with the 
immunosuppressive state, also named immunoparalysis, when immune paralysis occurs 
due to exaggerated anti-inflammatory response [166, 183]. Immunoparalysis leads to 
unproductive clearance of septic foci and renders the septic patient more vulnerable to 
secondary infections, as well as reactivation of latent infections [185]. 
Surprisingly, the same study revealed that no major cell death was presented in organs 
like heart, lung, liver and kidney where often demonstrated significant dysfunction in 
advanced sepsis [182, 186]. In sepsis, the distribution of microvascular flow is altered 




and diminished adenosine triphosphate (ATP) production were discovered in biopsied 
muscles of septic patients with organ dysfunction and poor outcomes [188, 189]. 
However, it was proved that tissue oxygen tension within organs increased [190]. Hence, 
organ dysfunction in sepsis could be derived from tissues' inability to consume oxygen 
and subsequent mitochodrial dysfunction [191, 192].  
The above section are the known pathologies of sepsis. With the metioned complex 
mechanisms, identification of more reliable and effective biomarkers is of utmost 
importance to guide treatments. 
 
1.4.3 Diagnosis and Markers of Sepsis 
SIRS criteria (Figure 1.6) was applied for the diagnosis of sepsis. When the requisite 
two or more SIRS conditions were observed in patients with suspected infection, sepsis 
was confirmed [193]. Yet, with cases where SIRS criteria showed poor discriminant and 
concurrent weak validity, this approach was considered to be unhelpful [194, 195].  
As recommended by the Third International Consensus, for clinical operationalisation, 
organ dysfunction can be characterised by an increase in the Sequential [Sepsis-related] 
Organ Failure Assessment (SOFA) score (as seen in Table 1.2) of 2 points or more [155]. 
In out-of-hospital or emergency department, adult patients with suspected infection can 
be rapidly identified if they have at least 2 of the following clinical criteria that together 
establish a new bedside clinical score termed quickSOFA (qSOFA) (Figure 1.6). 
Patients with septic shock can be clinically identified by a vasopressor requirement to 




than 2 mmol/L (>18 mg/dL) in the absence of hypovolemia. The criteria for sepsis and 
septic shock were illustrated in Figure 1.7. 
SIRS (Systemic Inflammatory Response Syndrome) Criteria
❖ Temperature >38°C or <36°C
❖ Heart rate >90/min
❖ Respiratory rate >20/min or PaCO2 <32 mm Hg (4.3 kPa) 
❖ White blood cell count >12 000/mm3 or <4000/mm3 or >10% immature bands
qSOFA (quick SOFA) Criteria
❖ Respiratory rate ≥22/min
❖ Altered mentation
❖ Systolic blood pressure ≥100 mm Hg
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Figure 1.7. Operationalisation of clinical criteria identifying patients with Sepsis and Septic Shock. 
Figure adapted and modified from [193]. 
 
Sepsis is a time-sensitive condition, with delays in either diagnosis or therapy leading to 
increased mortality [196]. Faster diagnosis of sepsis could potentially reduce mortality, 
shorten length of stay, and lower hospital costs [197]. Hence, the discovery of new 
biomarkers as a tool for aiding early diagnosis and rapid appropriate therapies for 
patients with sepsis can improve patient outcomes greatly [198]. In recent years, more 
than 150  sepsis biomarkers were reported in a wide range of studies [199]. From those, 
biomarkers including proteins such as procalcitonin, presepsin, C-creative protein 
(CPR), CD64, soluble-urokinase-type-plasminogen-activator-receptor (suPAR), 
soluble triggering receptor expressed on myeloid cells 1 (sTREM-1), IL-6, IL-27, cell-




Table 1.2. Sequential [Sepsis-related] Organ Failure Assessment Score. Table adapted from [203]. 
System Score     
0 1 2 3 4 
Respiration      
PaO2/FIO2, mm Hg (kPa) ≥400 (53.3) <400 (53.3) <300 (40) <200 (26.7) with 
respiratory support 
<100 (13.3) with 
respiratory support 
Coagulation      
Platelets, ×103/μL ≥150 <150 <100 <50 <20 
Liver      
Bilirubin, mg/dL 
(μmol/L) 
<1.2 (20) 1.2–1.9 (20–32) 2.0–5.9 (33–101) 6.0–11.9 (102–204) >12.0 (204) 
Cardiovascular MAP ≥70 mm Hg MAP <70 mm Hg Dopamine <5 or 
Dobutamine (any dose)  
Dopamine 5.1–15 
or epinephrine ≤0.1 
or norepinephrine ≤0.1  
Dopamine >15 or 
epinephrine >0.1 
or norepinephrine >0.1  
Central nervous system      
Glasgow Coma Scale 
score  
15 13–14 10–12 6–9 <6 
Renal      
Creatinine, mg/dL 
(μmol/L) 
<1.2 (110) 1.2–1.9(110–170) 2.0–3.4 (171–299) 3.5–4.9 (300–440) >5.0 (440) 
Urine output, mL/d    <500 <200 




As a result of the growing appreciation of the important role of immunoparalysis, the 
focus shifts from inhibiting to stimulating the immune response [204]. Therefore, there 
is a clear need for suitable biomarkers of a patient’s immune status to guide relative 
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Figure 1.8. Mechanisms of immunoparalysis and markers. TNFα, Tumor necrosis factor-α; IL, 
interleukin; mHLA-DR, Human Leukocyte Antigen on cell surface of monocytes; PD-(L)1, 
Programmed Death (ligand) 1; CTLA-4, Cytotoxic T-Lymphocyte Antigen 4; BTLA, B- and T-
lymphocyte attenuator; LAG-3, Lymphocyte-activation gene 3; TIM-3, T-cell immunoglobulin and 
mucin protein 3; IL-7R, interleukin-7 receptor; sFAS, soluble Fas; FAS-L, Fas ligand; T-regs, 
CD4+CD25+ T-regulatory cells; IL-1ra, IL-1 receptor antagonist; TGF-β, transforming growth factor-
β. Figure adapted and modified from [204].  
 
Results from previous research indicate that a ratio or panel of markers may have a more 
robust power in terms of outcome prediction when compared to a single marker, since 
markers often show mutual correlation [205, 206]. Additionally, when assessing the 
potential value of markers of sepsis, individual patient characteristics should be taken 




malignancies, expression of BTLA may be increased in cancer patients regardless of the 
latent septic condition [185]. Lastly, the kinetics of the established biomarkers need to 
be considered, since longitudinal monitoring seem to be of more prognostic validity than 
a single measurement. 
 
1.4.4 Treatments for Sepsis 
The prompt treatment for sepsis and septic shock with antibiotics is critical in association 
with decreased mortality [207]. Broad-spectrum antibiotics (i.e. a single gram-positive 
agent, a single gram-negative agent, a single anti-fungal agent) are normally given first 
as the identification of a specific type of infection is time consuming [208]. These are 
designed to work against a wide range of known infectious bacteria and usually cure 
most common infections. Once a specific bacterium has been recognised, a more focused 
antibiotic can be used [209]. Moreover, combination therapy, defined as the use of two 
different classes of antibiotics for a single pathogen, has been broadly discussed [196, 
210]. The adoption of a combination of antibiotics can cause resistance and microbiota 
disruption. However, the utilisation of combination therapy can not only accelerate 
pathogen clearance, but also assure that pathogen is sensitive to one antibiotic, with 
regard to significant microbial resistance [196]. The most common combination therapy 
includes a beta-lactam with an aminoglycoside, fluoroquinolone or macrolide [211].  
Besides, the administration of intravenous fluids to improve circulation, perfusion, and 
oxygen delivery is an essential principle in sepsis management [212]. It is recommended 




30 ml/kg of crystalloid intravenously within the first 3 hours [213]. Also, medications 
like vasopressors are used if low blood pressure is inspected, given that oxygen demand 
goes up for sepsis patients [214]. 
As the importance of the immunoparalysis during sepsis is increasingly being 
acknowledged, a few immunostimulatory agents such as granulocyte-macrophage 
colony stimulating factor (GM-CSF) and interferon γ (IFNγ) that have shown 









1.5 Metabolomics and Its Mechanisms  
1.5.1 Metabolomics 
Metabolomics is derived from the concept that changes in tissues or bio-fluid can be 
indicators of diseases [218]. The essence of metabolomics lies in that metabolic status 
represents the global physiological state in the living organism [219]. Metabolomics 
involves comprehensive and simultaneous systemic profiling of metabolite levels in a 
biological system as well as their fluctuations that reflect the response to 
pathophysiological stimuli, genetic modifications and the surrounding environment 
[220, 221].  
Metabonomics is another terminology often used interchangeably with metabolomics 
since the analytical and modelling procedures are identical [218]. Metabonomics is 
defined as ‘the quantitative measurement of the multiparametric metabolic responses of 
living systems to physiological stimuli or genetic modifications’ [222]. The emphasis of 
metabonomics is the metabolic shift over time and interpretation of differences among 
groups attributable to pathophysiological or genetic stimuli, while metabolomics focus 
on unbiased analysis of the composition of small molecule metabolites in a given 
biological tissue or fluid, under a specific set of environmental conditions [222]. 
However, the divergence between these two terms is philosophical rather than technical. 
Metabolomics is an integral part of large scale ‘-omics’ study, and it constitutes ‘system 
biology or medicine’ together with genomics, transcriptomics and proteomics (Figure 
1.9). Genomics is the science of the genomes, initially dedicated to the determination of 




of both genes and proteins [223]. The leading power behind genomics has been, without 
a doubt, the Human Genome Project. It began in 1990, and achieved its goal of 
sequencing the three billion base pairs in the human genome in 2003 [224]. Genome is 
the total DNA of the studying subject that contains the information for the synthesis of 
functional proteins [225]. This information needs to be transcribed into mRNA first, 
following by the synthesis of protein based on the mRNA template. The systemic study 
of the complete set of mRNAs at a specific timepoint is called transcriptomics [225]. 
Furthermore, proteomics analyses are the global translated proteins from mRNA and 
their interactions directing the activities of each cell [226]. Metabolomics is regarded as 
an extension to transcriptomics and proteomics. It can provide a functional signature of 
phenotypes for the upstream biochemical information obtained from genes, mRNAs, 



















Figure 1.9. A schematic diagram of systems approach to biology. The diagram shows that metabolites are the terminal downstream products of genomes, transcriptomes, 




Metabolomics, regarded as the apogee of system biology, has a number of inherent 
advantages compared to other ‘-omics’ techniques [228]. First, since metabolites are the 
terminal downstream products of the gene expression and protein expression, 
monitoring the perturbations in a pool of metabolites could reflect underlying disease 
pathology, disease prognosis and further diagnosis [229, 230]. Next, metabolomics can 
react rapidly to stimuli or changes, therefore it is capable of presenting the most current 
view of the system [231]. Moreover, metabolic pathways have been conserved through 
evolution, which denotes that metabolic pathways are comparable in rodents and 
humans. Hence metabolic signatures identified in mechanistic and therapeutic studies 
for animal models can be sometimes translated into human studies [232]. Additionally, 
the living style and surrounding environment would greatly influence metabolism, 
which is challenging to unravel their effects from gene-related outcomes. Metabolomics 
can resolve these issues by monitoring the global consequences of all involving factors 
regardless of any single contribution to that consequence [218]. Lastly, compared to 
genomics and proteomics, metabolomics is relatively cost effective and timesaving, and 
can be applied to various easily accessible biofluids such as serum, plasma, CSF, urine, 
and peripheral tissues, thus highlighting the clinical utility of this approach [233].  
Biomarker is a key terminology in metabolomics field. A biomarker or a biological 
marker is defined as ‘a characteristic that is objectively measured and evaluated as an 
indicator of normal biological processes, pathogenic processes, or pharmacologic 
responses to therapeutic interventions’, according to the U.S. national Institute of 
Health (NIH) Biomarker Definitions Working Group [234]. Another definition 
suggested by the World Health Organization (WHO) provides a more generalised 




a biological system and a potential hazard, which may be chemical, physical, or 
biological. The measures response may be functional and physiological, biochemical at 
the cellular level, or a molecular interaction’ [235]. Biomarker is the subgroup of medical 
signs which can be measured precisely and reproducibly in aiding clinicians to 
determine disease onset or progression, disease risk factors and the effect of treatments 
[234, 236]. However, biomarkers may but do not necessarily be applied to assess 
patients’ experience, functions or survivals [237].  
Basically, the goal of biomarker discovery is to construct a predictive model that can 
recognise the difference underlying groups and classify the study objects [238]. To 
classify samples into specific groups (e.g., healthy vs. diseased), high sensitivity and 
specificity are required for biomarkers, while ease-of-use is also a principal factor [238, 
239]. The discovery of novel biomarkers for disease diagnosis and prognosis mainly 
involves the application of large-scale ‘-omics’ technologies, such as genomics, 
transcriptomics, proteomics and metabolomics [225]. With the combination of these ‘-
omics’ technologies, measuring multiple biomarkers simultaneously to confirm disease 
onset and progression has captured the attention of clinicians and researchers [240]. 
Typical biomarkers include body temperature (for fever), blood glucose levels (for 
diabetes), cholesterol level (for coronary and vascular disease), and BRCA1 mutations 
(genetic marker for breast and ovarian cancer) [238, 241]. 
The feasibility of metabolomics for biomarker discovery is supported by the theory that 
metabolites are important participants in biological systems and that diseases cause 
disruption of biochemical pathways [242]. The discovery of metabolomic biomarkers 




discussed later in 1.5.3 with more details. Apart from discovery, there are other major 
steps along the path of translating a diagnostic biomarker to the clinic, such as pre-
validation of biomarkers,  analytical development, validation of biomarkers and 
commercialisation [243].  
 
1.5.2 Analytical Techniques Applied in Metabolomics 
The overall size of the metabolome remains elusive in the metabolomics field, but it is 
estimated to range from tens of thousands to hundreds of thousands of small molecules 
[244, 245]. Recent development in analytical technologies have allowed measurements 
of dynamic changes in many molecules from biological sample at the same time.  
These technologies include both spectroscopic approaches like ultra violet (UV), 
infrared (IR), high resolution nuclear magnetic resonance (NMR) spectroscopy and 
mass spectrometry (MS); and chromatographic approaches, such as liquid 
chromatography (LC), gas chromatography (GC) and capillary electrophoresis (CE), 
as well as hyphenated techniques, e.g., LC-MS and GC-MS [246]. However, no 
analytical techniques are available for the analysis of the entire complex nature of the 
metabolome content. Often a compromise has to be made depending upon a range of 
criteria such as time frame, cost, properties of the analytes, sensitivity and mass accuracy 
of instrumentation and the choice of biofluids as different techniques have their own 
challenges [232]. Generally, multi-parallel techniques are required in metabolic 




NMR spectroscopy and MS coupled with chromatographic techniques are the main 
options in metabolomics studies (Table 1.3)[247, 248].  
 
1.5.2.1 Nuclear Magnetic Resonance (NMR) Spectroscopy 
NMR spectroscopy is a form of absorption spectroscopy. In a magnetic field, based on 
the absorption of certain nuclei in the molecule and the characteristics of the sample, 
electromagnetic radiation of different radiofrequencies can be absorbed [249]. NMR 
spectroscopy in principle works by measuring energy differences between two spin 
states of certain nuclei when the absorption occurs with the aid of an external magnetic 
field [250]. The atomic nuclei include 1H, 13C, 15N, 19F and 33P. Amidst them, 1H NMR 
spectroscopy has been employed widely in metabolomics due to the natural abundance 
of hydrogen atom in metabolites [251].  
As one of the most popular and powerful spectroscopic techniques, NMR spectroscopy 
is well known for its inherent quantitative precision and high throughput manner [252]. 
Signal intensity of individual atom in an NMR spectrum is proportional to its molar 
concentration, enabling direct comparison among all features without the need of 
calibration curve [253].  
Further, the structural elucidation ability of NMR spectroscopy allows rigorous analysis 
of unknown entities in complex mixtures, such as crude extracts, cell suspensions, intact 
tissues, or even whole organisms [219, 250]. Metabolite structural identification also 
allows detection of atomic positions of isotope labels (e.g., 2H, 13C, or 15N) in various 




maps of biochemical networks can be profiled by applying NMR spectroscopy [257, 
258].  
In addition, it requires simple sample preparation and facilitates the high throughput 
analysis to a large extent [259]. Sample preparation in NMR analysis is minimal with 
little or no physical/chemical treatment by adding a small amount of buffer and D2O. 
With the unprecedented speed and robotic flow-injection method, a standard NMR 
spectrum can be obtained within a few minutes [260]. Another advantage of NMR 
spectroscopy is that it is a non-destructive technique [261]. This feature makes it 
possible for samples to be re-analysed by NMR or be re-used by other analytical 
platforms, which has great importance in the study of metabolomics [246].  
In summary, NMR is an ideal analytical platform for the metabolomic field for universal 
merits. However, it has a few drawbacks, and the relatively poor sensitivity is a 
weakness which limits the observation to around hundreds of metabolites, accounting 
less than 10% of the whole metabolome in an organism [262]. Another limitation is the 
spectral complexity with overlapping of signals, compromising the clear identification of 
features [253]. 
 
1.5.2.2 Mass Spectrometry (MS) 
Mass spectrometry is another mainstay technique in metabolomics research and it has 
undergone extensive development over the past few decades [246]. In a mass 
spectrometer, analytes can be detected after selection when they are charged, even with 




differences between two spin states of a nuclei is too weak to be measured and hence 
requires a much higher sample concentration [263]. Because of its high sensitivity when 
compared to NMR spectroscopy, MS allows detection and measurement of picomole to 
femtomole concentrations of numerous primary and secondary metabolites [264]. In 
addition, MS provides spectral information which contributes to the metabolite 
identification, either through the measurement of molecular mass with high accuracy or 
by the collection of fragmentation ions [265].   
MS performs the analysis by three steps: transforming analytes into gaseous ions, ion 
separation according to their mass/charge (m/z) ratio and detecting the ionized analytes 
[266]. Modern MS offers a variety of ionization and mass analyser technologies with 
different operational principles and functions [240]. In the metabolomics field, the most 
common ionisation techniques are electrospray ionization (ESI), atmospheric pressure 
chemical ionization (APCI) and atmospheric pressure photo ionization (APPI), with the 
characteristic of ionizing metabolites of a wide range of polarity (Figure 1.10) [267]. 
These techniques are especially prominent in untargeted analysis due to their ‘soft’ 
ionization feature, generating little or no fragmentations which can aid identification of 
unknown metabolites [267]. Other often applied techniques including matrix-assisted 
laser desorption ionization (MALDI), desorption ESI mass spectrometry (DESI) , 
nanostructure-imaging MS (NIMS) and secondary ion MS (SIMS) are imaging mass 
spectrometry techniques and those can reveal the localization of selected metabolites 






















Figure 1.10. Application of soft ionization techniques, ESI, APPI and APCI. ESI, electrospray 
ionization; APPI, atmospheric pressure photo ionization; APCI, atmospheric pressure chemical ionization. 
Figure adapted and modified from [267]. 
 
Mass analysers can be categorised based on the different resolving powers. High/ 
Ultrahigh resolution MS include Fourier transform-Ion cyclotron resonance-MS (FT-
ICR-MS), orbitrap and time of flight (TOF) [273]. They provide accurate mass 
measurements and precise metabolite quantification. Low resolution MS such as ion 
trap and single quadruples are also utilised in metabolomics. Each of the preceding 
analysers has its own advantages and disadvantages. And the selection of mass analysers, 
as well as ionization techniques, depends on the aim of the project, throughput and 
instrumental costs [274]. Mass spectrometer can also be operated in tandem mode 
(MS/MS) where second stage of MS (MS2) works in sequence, separating and 




As mentioned earlier the main strength of MS is sensitivity. However, it also has 
limitations. The quantification capability of MS is not as reliable as NMR spectroscopy. 
To obtain accurate quantification for a specific metabolite, an isotope-labelled standard 
with known concentration must be added during sample treatment as the internal 
standard. This strategy can be costly and the availability of labelled endogenous 
standard is scarce, which makes it especially impractical for untargeted analysis [275]. 
Another drawback of MS is the biased measurement. MS can only detect metabolites 
that can be turned into gaseous ions, and in order to increase the detecting coverage of  
metabolites, biological samples often have to undergo multiple steps of sample 
preparation [276]. Additionally, multiple components entering the MS at the same time 
can impact ionization and cause ion suppression skewing the measurement of molecules.  
MS can be employed in two modes, standalone (direct infusion MS, DIMS) or coupled 
with chromatography. DIMS approach is popular in metabolomics domain because it is 
a time saving and high throughput screening tool. With the availability of advanced MS 
instruments (FT-ICR-MS and orbitrap) that provide both high mass resolution and high 
mass accuracy, DIMS is being utilised broadly [277].  
Known disadvantages of DIMS, include ion suppression co-elution of metabolites into 
the mass spectrometer, the production of complex spectra and the limited metabolite 
identification to putative annotations at best [278, 279]. In order to surmount the 
challenges that occurred during DIMS analysis, MS is often coupled with 





1.5.2.3 MS coupled with Chromatography 
Separation techniques coupled with MS have been extensively utilised in metabolomics. 
The approach combines the separation power of chromatographic technologies with the 
high sensitivity and selectivity of MS.  Separation prior to detection reduces the matrix 
effect (where the matrix (eg. urine, plasma or serum) coextracted with the analytes can 
either enhance or weaken the signal response), and ion suppression that enables more 
accurate identification and quantification of metabolites [281]. Currently, there are 
three separation techniques incorporated in MS-based metabolomics, namely gas 
chromatography (GC), liquid chromatography (LC) and capillary electrophoresis (CE). 
The application of GC-MS in metabolomics can trace back to the 1950s, it was 
described as the gold standard even though it has its own limitations those will be 
discussed later [266]. Now it is still one of the most employed platforms for 
comprehensive analysis of metabolites, especially for hydrophilic molecules [282]. The 
combined technique provides high sensitivity, reproducibility, and resolution, so that it 
can be used in trace analysis [283].  
Capillary columns with greatly increased separation efficiency when compared with 
packed column is commonly chosen [264]. In addition, the constant hard ionization, 
electron impact (EI) ionization energy of 70eV, offers reproducible mass spectra and 
complete information of compound fragments [284, 285]. These allow more simplified 
metabolite identification by comparing retention time and standardised mass spectra 
data to those in public and commercial reference libraries [286-288]. In metabolomics, 
GC coupled to single quadruple MS is often adopted due to its reliability, effectiveness 




However, only volatile and thermostable compounds can be detected through this 
method [285]. Non-volatile compounds need to be converted into volatile forms 
through derivatization prior to analysis [282]. Generally, a two-step derivatization is 
required, firstly oximation and subsequently silylation [289]. Since anhydrous condition 
is needed for derivatized reactions, any presence of water would interrupt the process. 
Also, the drying process with continuous heating may lead to the loss of volatile 
compounds [266, 290].  
Since GC-MS is less adaptable to large and highly polar metabolites due to their poor 
volatility even after being derivatized. Using other chromatographic tools such as LC 
can analyse such polar compounds. LC-MS is an important technique in metabolomics 
in association with its flexibility [291].  
Normal-phase (NP) or reversed-phase (RP) columns can be employed for LC analysis, 
while both positive and negative ionization can be applied for MS to maximize the 
metabolites coverage [292]. Hydrophilic interaction liquid chromatography (HILIC) 
which is ideal for highly polar and ionic metabolites has also been widely applied to 
provide a complementary view of metabolome along with RP-LC [293]. In addition to 
the diversity of columns, different combinations of mobile phases (isocratic or gradient) 
further allow tailored separation of metabolites of interest [294]. The appearance of 
ultra-high-performance liquid chromatography (UHPLC), incorporating with even 
smaller particle sizes (sub-2μm) in column and a pump with a maximum pressure of 100 
MPa, yields significantly improved resolution, sensitivity and even the speed of LC 




These advantages have allowed LC-MS to be the dominant analytical platform in 
metabolomics. Yet, the development of LC-MS was once hampered because of a 
number of limitations [294]. The major weakness is the inconsistent quantitative 
precision caused by analytical variation. Various combinations of columns and mobile 
phases enable LC-MS to be flexible, but also sacrifice analytical variation such as drift 
of retention times, alteration of intensity values, and occasional modification of m/z 
values [296]. To assess these analytical variations, quality control (QC) samples are 
suggested to be repeatedly analysed throughout the entire experiment [297]. QC 
samples are aliquots of a sample pooled from all analysing samples. By inspecting QC 
samples along the whole run, the presence and types of variations can be evaluated.  
CE-MS is another valuable liquid phase technique because of the alternative separation 
mechanism involved [296]. CE which separates analytes based on the charge and size is 
particular suitable for separation of highly polar and ionic molecules, whist neutral 
metabolites can be separated via employing charged surfactants [298]. CE-MS analysis 
is fast and efficient with minor sample pre-treatment and minimum organic solvent 
consumption [280]. Nevertheless, the application of CE-MS is still relatively limited in 
metabolomics field, mainly because it suffers from poor detection sensitivity and 
robustness [299].  
Furthermore, the innovation of two-dimensional (2D) separation methods has boosted 
separation efficiency and peak capacity to a significant extent [280]. 2D separation 
techniques facilitates the analysis of complex biological samples with an unsurpassed 




dimension separation [300]. LC ×LC and GC × GC techniques have been applied in 
numerous metabolomics studies, demonstrating satisfied separation [301, 302]. 
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1.5.3 Data Treatment Strategies in Metabolomics 
Current metabolomics data analysis strategies are usually categorized into non-targeted 
and targeted approaches for variable selection following data extraction and 
preprocessing. In the data treatment stage, non-targeted metabolomics approach is 

































Figure 1.11. A schematic diagram of data treatment workflow in metabolomics. After conducting data 
extraction, pre-processing and processing, sample cohorts can be subjected to untargeted and targeted 
metabolomics analyses. Often, non-targeted analysis can also be followed by targeted analysis once 
relevant metabolites are selected from multivariate analysis. 
 
Untargeted or global metabolomic analysis allows for an assessment of the metabolites 
extracted from a sample and can reveal novel and unanticipated perturbations [240]. 
Untargeted analyses are most effective when implemented in a high-resolution mass 




advantage is that it offers an unbiased means to examine the relationship between 
interconnected metabolites from multiple pathways [303]. In the data pre-treatment 
stage, there are several platforms available for a series of data processing procedures 
including peak detection, peak alignment and peak matching (e.g., XCMS, MZmine, 
TagFinder, MarkerLynx, and MetaboAnalyst) [304-307]. Usually, each feature 
(variable) can be regarded as a dimension, and each sample can be represented by the 
variables information. Every sample has a unique coordinate in the hyperspace 
consisting of all variable dimensions [308]. Since the data set of non-targeted 
metabolomics is extremely large, the application of computational classification tools 
that will be discussed later can ease the process of extracting the metabolites of interest 
from a big data matrix.  
Targeted metabolomic analyses measure the concentrations of a predefined set of 
metabolites. Specific metabolites of interest can be directly identified or verified in the 
databases. This type of analysis can be used to obtain exact concentrations of 
metabolites identified by untargeted metabolomics, providing analytical validation 
[309]. The quantitation/semi-quantitation of interested metabolites could be achieved 
by normalisation with internal standard, external standard and total ion current.  Among 
these methods, the comparison between samples and standards provide more confident 
and accurate information. A standard curve for a concentration range of the metabolite 
of interest is often prepared, so that accurate quantification can be gained. For univariate 
analysis, according to the sample size involved in studies, non-parametric or parametric 
statistical tests could be applied for metabolites concentration comparison between or 




In addition, network modelling and pathway-mapping tools can help us to understand 
the parts that identified metabolites play in relation to each other and in biological 
aberrations. Thereafter, metabolites can be placed into context with upstream genes and 
proteins to lead mechanistic investigations through established and comprehensive 
metabolic network resources like Kegg [311].  
 
1.5.3.1 Computational classification tools 
Metabolomic data analysis becomes increasingly challenging when dealing with clinical 
samples with diverse demographic and genetic backgrounds and various pathological 
conditions or treatments. Many classification tools, such as multivariate analysis (MVA), 
and machine learning algorithm, have been successfully used in metabolomics [312]. 
MVA is one of the statistical methods which analyse observations (samples) and more 
than two variables [313]. It has shown high efficiency and reliability for the analysis 
modelling of complex metabolomics data.  MVA conducts dimension reduction while 
retaining the maximum variability and extracting the metabolites of interest from 
complicated matrix [238]. 
Principal component analysis (PCA) is a non-supervised multivariate method and is 
most widely used in metabolomics study, to visualize the overall trend within the 
multidimensional dataset [314]. This non-supervised method is used to simply classify 
groups and check outliers, giving that sample identity is unknown. Moreover, the 
supervised multivariable analysis techniques, e.g., partial least squares (PLS), PLS-




discriminant analysis (OPLS-DA), use the prior information about sample classes, 
giving better information in biomarkers discovery based on distinguish features related 
to different groups [315].  
However, it has long been known that PLS (and all of its variants, PLS-DA, OPLS, 
OPLS-DA, etc.) can easily generate models that over fit the data, and that over fitting 
of the model needs to be assessed using cross-validation [312]. Multivariate analysis of 
metabolic fingerprinting datasets is performed most often with the linear projection-
based methods of PCA, PLS and OPLS, but these are by no means the only tools 
available. Supervised machine learning methods include random forest (RF) and logistic 
regression are gaining extensive attentions in metabolomics field. 
Random forest (RF), is reported as an excellent classifier with the following advantages: 
simple theory, fast speed, stable and insensitive to noise, little or no overfitting, and 
automatic compensation mechanism on biased sample numbers of groups [316]. It is a 
combination of tree-structured predictors (decision trees). Each tree is created via a tree 
classification algorithm and generates a unit vote for the most popular class based on a 
bootstrap sampling (random sampling with replacement) of the data. The simplest 
random forest with random features is formed by selecting randomly, at each node, a 
small group of input variables to split on. The size of the group is fixed (normally set as 
the square root of the number of total variables) throughout the process of growing the 
forest. Each tree is grown by using the CART (classification and regression tree) 
methodology without pruning [312]. 
The standard logistic regression model predicts the probabilities of a sample being a 




difficulty handling a large number of variables [317]. Typically, variable selection is 
performed before fitting a standard logistic regression model. Variable selection is 
mainly performed to include clinically relevant and statistically significant variables into 
the model, while excluding noise or redundant variables [318]. Purposeful selection, best 
subset, stepwise selection and bagging method are common procedures for this purpose 
[319]. Penalized/regularised logistic regression, a variant of the logistic regression model, 
can handle a large number of variables and has a built-in stepwise variable selection 
process [320]. Apart from the previously mentioned supervised machine learning 
approaches, hierarchical clustering analysis (HCA) and K nearest-neighbour clustering 
may also be applied to multivariate spectral data to reveal differences between classes 
without supervision.  
The classification performance of classification tools can be evaluated and compared 
using several approaches: cross-validation, R 2/Q 2 plot, ROC, reduction of variable 
number and utilising training/test datasets. These are important aspects for a classifier 
to assess prediction ability and stability, overfitting, diagnosis potential, and variable 
number dependence. 
 
1.5.3.2 Metabolites identification and databases 
Initial putative metabolite identifications can be made based on the accurate m/z of the 
mass spectral ion (parent ion). This is aided using comprehensive metabolite databases 
such as METLIN, Human Metabolome Database (HMDB), and MassBank [321-323]. 
Further identification can then be carried out on the isolated ion, followed by matching 




(daughter ions) and retention time information to distinguish the ion from structural 
isomers [240].  
The identification of metabolites in metabolomic samples is challenging as it has to 
discriminate (i) metabolites of different nominal masses; (ii) metabolites with the same 
nominal mass but different molecular formulas and monoisotopic masses; and (iii) 
metabolites with the same nominal and monoisotopic mass, but different chemical 
structures (including chirality and isomerism) [324]. Therefore, The Chemical Analysis 
Working Group of the Metabolomics Standards Initiative has reported four levels of 
metabolite identification confidence (Table 1.4) to aid with reporting metabolites 
identification [325].  
Table 1.4. The four levels of metabolite identification confidence. Defined by the Metabolomics 
Standards Initiative [325]. 
Level Confidence of Identity  Evidence 
1 Confident identification 
of compounds 
Comparison of two or more independent and orthogonal 
properties (RT, m/z, fragmentation mass spectrum) with an 
authentic chemical standard analysed under identical 
analytical conditions 
2 Putative annotation of 
compounds  
Based upon physicochemical properties and/or spectral 
similarity with public/commercial spectral libraries, without 
reference to authentic chemical standards 
3 Putative annotation of 
compound classes 
Based upon characteristic physicochemical properties of a 
chemical class of compounds, or by spectral similarity to 
known compounds of a chemical class 
4 Unknown compounds Although unidentified and unclassified, these metabolites 
can still be differentiated and quantified based upon spectral 
data 





1.6 Application of Metabolomics in Liver Related Diseases 
Metabolomics, or small-molecular metabolic fingerprinting, is an emerging discipline 
with a wide-range of applications. Metabolomics has been applied together with the 
pattern recognition and multivariate statistical analysis on complex datasets [233, 326]. 
Studies based on metabolomics have been expanding to apply in a variety of fields: e.g. 
Alzheimer’s disease, anti-doping, gut microbial activities, and liver related diseases 
[327-329].  
For the application of metabolomics in liver transplantation, studies about early allograft 
dysfunction and potential biomarker of DBD transplant type have been conducted [55]. 
There is also research performed in tissue metabolomics of hepatocellular carcinoma 
(HCC), revealing that monounsaturated palmitic acid can act as a marker for HCC 
progression and poorer patient survival [330]. Additionally, Gonzalez et al. found 
increased serum levels of several metabolites, including those also discussed in this thesis, 
LysoPC (18:0) and PE (34:2), were significantly modified due to acute liver injury 
while showing a high correlation with the degree of liver damage determined by 
histological examination of the livers [331].  
The therapeutic effect of herbal medicine dose on cholestasis was investigated using 
metabolomics coupled with multivariate data and pathway analysis. Several bile acids 
and amino acids were found to be associated with the dose influence [332]. A study 
conducted by Aoki et al. observed that antioxidative and cytoprotective metabolite 
levels were markedly increased in urine of cholestatic rats, while the concentrations of 




NMR metabolomic study has been performed in cholestatic rats in an attempt to use 
urinary biomarkers to distinguish the two mechanisms (extrahepatic and intrahepatic) 
[334]. 
In the field of sepsis, a global metabolomic profile in plasma broadly differed between 
survivors and non-survivors. From 423 identified small molecules, 17 % of them showed 
significant differences between two groups. In the meanwhile, broad differences were 
also present in pathways of oxidative stress, bile acid metabolism, and stress response 
[335].  Izquierdo-García et al. were able to build a predictive model discriminating 
between septic and non-septic rats. The discriminant metabolites identified in lung 
tissue and serum include alanine, creatine, phosphatidylethanolamine, and myo-inositol 
[336]. 
Over the past decades, metabolomics has been utilised in the field of hepatology. There 
is no other organ like liver where such a plethora of both hydrophilic and lipophilic 
metabolites are metabolically interchanged [2]. The rates of metabolism and energy 
production and consumption found in the liver are speedy and non-comparable to other 
organs [337]. The hepatic metabolome is therefore a highly complex and dynamic flux 
of small metabolites. Overall, an extensive number of studies have applied metabolomics 
in order to identify 1) metabolites which would potentially be used as biomarkers for 
liver related diseases and 2) perturbations in metabolic pathways that reflect variations 
associated with disease pathology. Metabolomics has manifested its capacity of being an 






The liver is the source of a myriad of endogenous metabolites and precursors used by 
other organs, it also houses abundant detoxication enzymes that play crucial roles in an 
array of diseases. The previous section reviewed liver transplantation, cholestasis, sepsis 
and metabolomics. It highlighted metabolomics as an approach to further understand 
the biochemistry of liver related diseases and to facilitate the discovery of potential 
endogenous biomarkers. 
In this thesis, untargeted lipidomics with RP-MS technique will be employed for liver 
tissues from two different liver transplant donation groups, DBD and DCD, to compare 
the lipid fingerprints and determine whether differences in metabolite levels reflect tissue 
damage. Targeted lipidomics focusing on pro-inflammatory mediators, ceramides, will 
also be conducted to assist the understanding of IRI during liver transplantation. To 
extend the discovery from lipid studies, polar metabolites using an additional HILIC-
MS metabolomics method was applied in an untargeted discovery approach.   
Then both plasma and liver samples of mice from a cholestatic model were studied. Bile 
acid and lipid levels were measured using RP-MS methods to find lipid signatures 
associated with cholestasis. 
Lastly, RP-MS and HILIC-MS will be combined to investigate the full metabolic 
profile of liver and brain biopsies from mice in a septic model. Three machine learning 




 Lipidomics comparing DCD and DBD 
liver allografts uncovers lysophospholipids elevated 
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Liver transplantation is the most viable solution to a range of acute and chronic end-
stage liver diseases [338]. The global prevalence of liver disorders such as cirrhosis, 
hepatitis B and C and non-alcoholic fatty liver disease have resulted in a marked increase 
in the demand for transplantation [339-342]. However, widespread shortfalls in donor 
organ availability mean that the demand for transplantation greatly exceeds its actual 
occurrence [338]. This crippling donor shortage has led to the increase use of organs 
from ‘marginal’ donors [343, 344], including those obtained from donation after 
circulatory death (DCD). The use of DCD livers remains limited as organs are exposed 
to a significant period of warm ischaemia prior to retrieval and have poorer patient 
outcomes [345-347]. It is estimated that up to a fifth of donation after brain death (DBD) 
organs do not meet the strict clinical criteria for transplantation, and are thus discarded 
[348], compared with even higher losses reported for DCD grafts [16]. A primary goal 
of the pre-transplantation donor evaluation is determining whether the donor liver is 
more susceptible to graft dysfunction following transplantation [55, 56]. While the 
assessment is an important patient safeguard, it may also result in otherwise 
transplantable organs being discarded. Increasing the pool of available and 
transplantable livers by identifying specific pre-transplantation markers of liver damage 
is thus a high priority [57, 58].  
Elevated liver-enzyme levels are widely accepted as the standard for liver injury, 
however these tests lack specificity as they can be affected by medication and other 
syndromes [349]. Biomarker discovery in the context of liver pathophysiology has been 




markers in liver tissue, targeted and metabolite phenotyping strategies have been applied 
to find markers relevant to liver transplantation [351, 352], findings highlighted lipid 
associations to early allograft dysfunction (EAD) and recipient clinical outcomes [55, 
353-355].  
Due to different mechanisms implicated in brain death and circulatory death, as well as 
distinct retrieval procedures involved, it is important to obtain comprehensive 
interpretation of changes at metabolites level in both donation groups. Hence, the aim 
of this chapter was to identify more distinctive and reliable tissue damage or graft 
function biomarkers, which in the future could increase the pool of transplantable organs 
by discarding less viable grafts. 
Here, we investigate lipid fingerprints at both pre- and post-transplantation, using ultra-
performance liquid chromatography-mass spectrometry (UPLC-MS) in hepatic tissue 
in two distinct donor types: viz. DBD and DCD, the latter undergoing warm ischaemia 
events [356] . The main lipid differences between these two donor types were 
determined by an initial lipidomics screen (112 biopsies), which highlighted 12 targeted 
phospholipids that were reanalysed in targeted mode and univariate comparisons. After 
this, associations to clinical outcomes were investigated. The study workflow is 
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Figure 2.1. Study flowchart illustrates the overall design and analytical procedures from untargeted 
analysis to targeted analysis and associations of potential biomarkers to clinical outcomes. DCD, 
donation after circulatory death; DBD, donation after brain death; OPLS-DA, orthogonal projections to 
latent structures-discriminant analysis; LysoPC, lysophosphatidylcholine; CIT, cold ischaemia time; 
WIT, warm ischaemia time, EAD, early allograft dysfunction; IGF, Immediate Graft Function; AST, 





2.2.1 Chemicals and reagents 
All solvents, water, methanol, ammonium formate and methyl tertiary butyl ether 
(MTBE), were liquid chromatography–mass spectrometry (LC-MS) grade purchased 
from Sigma-Aldrich. Two internal standards, heptadecanoic acid (≥98% purity), 
tripentadecanoin (≥98% purity) for the reversed phase, were purchased from Sigma-
Aldrich. In-vial dual extractions were performed in amber glass high performance liquid 
chromatography (HPLC) vials with fixed 0.4 mL inserts (Chromacol: Welwyn Garden 
City, UK). 
 
2.2.2 Patients and biopsy collection  
This study received prior approval from the ethics committee at King’s College Hospital, 
and informed consent was obtained from all subjects. The methods were carried out in 
accordance with the approved guidelines. Overall 112 Tru-Cut tissue biopsies were 
obtained from liver allografts pre- and post-transplantation. The first (pre-transplant) 
biopsy was taken at the end of cold preservation, prior to implantation, and the second 
(post-transplant) biopsy was obtained approximately 1 hour after graft reperfusion. A 
separate biopsy was obtained for histopathological evaluation of donor steatosis. 
Biopsies were immediately snap-frozen in liquid nitrogen and stored at -80°C until 
extraction for LC-MS analysis. In all procedures, liver allografts were flash-cooled and 





Power calculations were performed for DBD (n=38) and DCD (n=18) participants using 
‘Gpower3.1’ (http://www.gpower.hhu.de/). Assuming a two-sided Type I error of 0.05 
and standard normal distributions for lipid molecules, this study has >80% power to 
detect differences between two groups based on our previous work [353]. 
 
2.2.3 Donors 
The study included two types of adult donors: DBD (n=38) and DCD (n=18). A wide 
spectrum of donor clinical data was collected for comparison among groups and for 
correlation with lipid levels. In the DBD group, 18 of the livers had mild steatosis (up to 
30% fat on biopsies), 6 had moderate steatosis (30–60% fat) and the remaining DBD 
grafts had none.  In the DCD group, 2 allografts were mildly steatotic, 6 allografts were 
moderately steatotic and the remainder were normal. In the DCD group, WIT was 
calculated from the time when systolic blood pressure was below 50 mmHg to the time 
of cold perfusion. Total WIT is the sum of Functional WIT, Hepatectomy time and 
Bench perfusion. The relevant donor data are included in Table 2.1. 
 
2.2.4 Recipients 
All recipients were patients with stable chronic liver disease who did not require 
hospitalization prior to transplantation. Indications of liver transplantation in the study 
include alcoholic liver disease (ALD), primary sclerosing cholangitis (PSC), hepatitis C 




transplantation, all patients received immunosuppressive therapy with tacrolimus and 
prednisolone. Recipients’ 14-day period of international normalized ratio (INR), AST, 
albumin, gamma-glutamyl transferase (GGT), bilirubin, alkaline phosphatase (ALP) 
and creatinine level were recorded. Graft performance was assessed based on level of 
AST, INR and bilirubin levels after transplantation [106]. According to graft 
performance, recipients were classified into two groups: showing EAD (n=15) and IGF 





Table 2.1. Summary of clinical data for liver donors and recipients. 
Donor DBD (N=38) DCD (N=18) p-value[b] 
Age(years) 53(25-82) 56(35-76) 0.494 
Gender(female/male) 22/16 9/9 0.774 
Hepatic 
steatosis 
No 14 10  
Mild (<30%) 18 6 0.470 
Moderate (30-60%) 6 2  
GGT (IU/L) [a] 54(6-208) 62(12-315) 0.686 
AST (IU/L) [a] 85(22-517) 137(15-392) 0.281 
Bilirubin (μmol/L) [a] 11(3-37) 11(4-26) 0.845 
ITU stay (days) 4(1-28) 3(1-10) NA 
Inotrop support (Y/N) 22/16 11/7 1 
Functional WIT (min)  21(9-33)  
Hepatectomy time (min)  29(13-57)  
Bench perfusion (min) NA 26(10-44) NA 
Total WIT (min)  75(46-100)  
CIT (min) 501(210-840) 430(84-720) 0.138 
Recipient DBD (N=38) DCD (N=18) p-value[b] 
Age (years) 44(20-65) 55(46-70) 0.003 
Gender (female/male) 17/21 6/12 0.563 
BMI (kg/m2) 25.6(18.4-34.6) 26.5(15.9-35.8) 0.357 






















AST (IU/L) [a] 1108(114-8075) 1968(309-10054) 0.075 
Bilirubin day 7 (μmol/L) 56(6-162) 65(12-175) 0.447 
INR day 7 1.04(0.86-1.21) 1.15(0.92-1.96) 0.567 
EAD/IGF 8/30 7/11 0.202 
DBD, donation after brain death; DCD, donation after circulatory death; GGT, gamma-glutamyl 
transferase; AST, aspartate aminotransferase; ITU, intensive therapy unit; WIT, warm ischaemia time; 
CIT, cold ischaemia time; BMI, body mass index; MELD, model for end-stage liver disease; ALD, 
alcoholic liver disease; PSC, primary sclerosing cholangitis; HCV, hepatitis C virus; HCC, hepatocellular 
carcinoma; BA, biliary atresia; EAD, early allograft dysfunction; IGF, immediate graft function.  
Continuous values are expressed as means (minimum-maximum); NA, not applicable. Total WIT is the 
sum of Functional WIT, Hepatectomy time and Bench perfusion. [a] Tested on the day of operation, [b] 





Sample preparation for all 112 biopsies and lipidomic analysis followed the procedures 
below [326]. Between 10 and 30 mg of tissue were obtained and transferred to a pre-
weight Eppendorf tube containing a steel bead. Then, 30 µL (per 10 mg of tissue) of a 
methanol: water mixture (4:1, containing the negative-mode internal standard 
heptadecanoic acid 10 µg/mL) was added and the samples were homogenized for 5 min 
at 25 Hz (10 cycles of 0.5 min) in a TissueLyser (Qiagen, MD, US). Following this, 70 
µl of the homogenate was added to an amber glass HPLC vial containing a 300 µl glass 
insert (Chromacol, UK). To this 200 µl of MTBE containing 10 µg/mL of positive-
mode internal standard (tripentadecanoin) was added, and the samples were mixed via 
vortexing at room temperature for 60 min. Then, 30 µl of high purity water was added 
and samples were centrifuged at 2500g for 20 min at 4 ºC. Another 35 µl of the 
homogenate from each sample was taken to form the pooled QC samples. Same 
procedures were followed for QCs extraction. 50 µl of the upper lipid-containing MTBE 
phase from all samples were then transferred to clean vials and injected onto the Waters 
ACQUITY ultra-performance liquid chromatography-quadrupole time of flight 
(UPLC-QToF) system directly from the vial. Two different ionization modes including 
positive and negative were performed for each sample (50 µl for each mode). QC sample 
was running in between every 8 samples. 
Samples were kept in the chamber with targeted temperature of 4 °C, and the injection 
volume is 5 µl with full loop function (20 µl loop size). Chromatographic separation for 
lipidomics was achieved using an Agilent Poroshell 120 EC-C8 column (150mm × 




operated in positive and negative ionisation mode. A gradient was employed consisting 
of 10 mM ammonium formate in water (mobile phase A) and 10mM ammonium formate 
in methanol (mobile phase B).  The solvent was delivered at a flow rate of 0.5 mL/min.  
For positive mode, the gradient consisted of 0 min (75% B), 23 min (96% B), 36 min 
(96% B), 36.5 min (100% B), 41.5 min (100% B) and 42 min (75%B).  The column 
was re-equilibrated at 75% B for 9 minutes prior to each injection.  For analysis in the 
negative mode, the gradient started at 75% B increasing linearly to 96% B at 23 min, 
then increasing further to 99.5% B by 23.1 min and maintained till 30 min, initial 
conditions were restored at 30.1 min to allow column re-equilibration till 35min. In 
terms of the mass spectrometric condition, for positive mode, a capillary voltage of 3.2 
kV and a cone voltage of 45 V were used. The desolvation gas flow was 400 L/hour and 
the source temperature was 120°C. All analyses were acquired using the lock spray to 
ensure accuracy and reproducibility; leucine enkephalin was used as lock mass (m/z 
556.2771 and 278.1141) at a concentration of 200 ng/mL and a flow rate of 10 μL/min. 
Data were collected in the centroid mode over the mass range m/z 100–1000 with an 
acquisition time of 0.1 seconds a scan. For negative mode, a capillary voltage of -2.6 kV 
and a cone voltage of 45 V were used. Desolvation gas flow and desolvation temperature 
were fixed at 800 L/h and 350 ºC, respectively. The reference solution (leucine 
enkephalin, m/z 554.2639) was infused with the same conditions describe in the positive 
mode. 
All data was processed within ‘XCMS’ package in ‘R’ (version 3.2) and exported into 
SIMCA version 13 (MKS Umetrics AB, Sweden) for multivariate analysis. Multivariate 
analysis included pre- and post-transplant matched samples n=112 (DBD n=76, DCD 




described as dependant variables, features or measurements, for multivariate analysis. 
OPLS-DA was then performed to select features based on covariance p[1] and 
correlation p(corr) value (p[1]>0.1, p(corr)>0.4 and p[1]<-0.05, p(corr)<-0.18). 
 
2.2.6 Intact Lipid Analysis 
Selected lipids were measured in the LC-MS data using Waters MassLynx software 
(Waters Corporation, Milford, MA), and peak areas were normalized to total ion count 
ratios. The identification (level 1 confidence) was performed by comparing the structure 
and fragmentation patterns in the MS2 data with standards [244, 321, 357].  
Median values were used to plot the heat-map using an open source ‘R’ (version 3.2) 
with ‘gplots’ package [358],  bean-plot of in each group was drawn in ‘beanplot’ 
package[359]. Levels in each group at pre- and post-transplantation stage as well as 
between DCD and DBD groups were examined with univariate non-parametric Mann-
Whitney test (2-sided), and Benjamini- Hochberg correction was applied to control the 
false discovery rate (FDR) [328]. All p values were represented as q values after 
correction. Lipids with q<0.01 were selected for clinical correlation analysis. 
 
2.2.7 Clinical correlations 
The selected lipids level in both EAD and IGF groups were investigated with Mann-
Whitney test (2-sided) to examine the lipids distribution differences, calculations were 




EAD was built using ROC curve for two combined LysoPCs (LysoPC (16:0) and 
LysoPC (18:0)) and three combined clinical data (donor AST, donor age and steatosis 
status) in ‘R’ with ‘pROC’ package. The prediction ability of these two curves was 
assessed by area under curve, accuracy, sensitivity and specificity. 
Linear mixed effects models were used to investigate the longitudinal associations 
between recipients’ 14-day AST, bilirubin and creatinine concentrations and each lipid 
pre-transplant levels. Data were scaled to obtain standard deviation of 1. The average 
baseline AST, bilirubin and creatinine concentrations and the average change in their 
concentrations over 14 days (follow-up time) was calculated for all subjects per visit 
(day) as a group (fixed effects) and subject-specific intercept and slope terms, which 
reflected deviation from the group average (mixed linear effects) were calculated. An 
interaction term between visit (day) and lipid pre-transplant levels was used to 
investigate whether the recipients’ longitudinal AST, bilirubin and creatinine 
concentrations (slope) was associated with lipid pre-transplant levels. All calculations 
included adjustment for age and gender for the 56 donors. All obtained p values were 
corrected for multiple comparisons and results given as q values. Linear mixed effect 





2.3.1 Clinical outcomes 
There were no significant differences between DBD and DCD groups in donors’ ages, 
EAD/ immediate graft function (IGF) distribution, liver enzymes, hepatic steatosis or 
serum bilirubin levels. Differences were observed in the recipients’ ages (p<0.01) 
between these two groups (Table 2.1). 
 
2.3.2 Lipidomics multivariate analysis and selected phospholipids 
To discover relevant lipid features, a PCA model (R2X=0.592, Q2=0.521) was initially 
constructed, although no obvious difference was observed. Then, an orthogonal 
projection to latent structures-discriminant analysis (OPLS-DA) model (Figure 2.2) 
among DBD and DCD grafts was built with n=112. The model’s figures of merit were 
R2X=0.659, R2Y=0.941 and Q2=0.58. R2X explains a feature percentage (65.9%) which 
is explained by this model, R2Y indicates that 94.1% of the group variance is interpreted, 
and Q2 shows the prediction ability of the model with 58%. 7-fold cross validation (CV) 
(CV p value=6.20x10-12) suggested its reliability. From the model, 12 features 
differentiated among 2 groups with p[1]>0.1, p(corr)>0.4 and p[1]<-0.05, p(corr)<-0.18 
were selected (Table 2.2). These selected 12 features consisted of 2 
lysophosphatidylethanolamines (LysoPEs), 2 lysophosphatidylcholines (LysoPCs), 6 
phosphatidylcholines (PCs) and 2 phosphatidylethanolamines (PEs). Donor age, 




showed low p[1] and p(corr) values and were not chosen as important variables. A heat 




Figure 2.2. OPLS-DA model from screen of lipidomics with n=112 (DBD=76, DCD=36) biopsies. a) 
Score plot of the model, R2X=0.659, R2Y=0.941, Q2=0.58, cross validation p value=6.20x10-12; b) S-plot 
of the model, features with p[1]>0.1, p(corr)>0.4 and p[1]<-0.05, p(corr)<-0.18 were selected (red circles), 
variables including donor age, steatosis status, WIT and CIT were clustered in the middle (blue circles). 
DCD, donation after circulatory death; DBD, donation after brain death; WIT, warm ischaemia time; 






Table 2.2. Identification of markers based on molecular weight, retention time and collision induced 




m/z Observed ion QC RSD (%) 
LysoPE (16:0) 3.46 452.28 [M-H]- 9.91 
LysoPE (18:0) 5.24 480.31 [M-H]- 7.86 
LysoPC (16:0) 3.42 496.33 [M+H] + 10.9 
LysoPC (18:0) 5.16 524.37 [M+H] + 20.3 
PE (34:2) 16.81 714.51 [M-H]- 4.61 
PE (38:4) 19.32 750.55 [M-H]- 4.51 
PC (34:2) 16.73 758.56 [M+H] + 19.5 
PC (36:4) 16.80 782.57 [M+H] + 8.92 
PC (36:3) 17.38 784.59 [M+H] + 7.66 
PC (36:2) 18.41 786.61 [M+H] + 10.6 
PC (38:4) 18.46 810.60 [M+H] + 1.77 
PC (38:3) 19.01 812.62 [M+H] + 11.4 
LysoPE, lysophosphatidylethanolamine; LysoPC, lysophosphatidylcholine; PE, 

















Figure 2.3. Heat-map showing distinct lipid profiles of DBD and DCD tissue in 112transplant samples. 
Values are median amounts per donor group at pre- and post-transplantation stages. A clustering 
analysis (dendrogram) shows which lipids differ most; red depicts high amounts and blue means low level. 
DCD, donation after circulatory death; DBD, donation after brain death; PE, phosphatidylethanolamine; 
PC, phosphatidylcholine; LysoPC, lysophosphatidylcholine; LysoPE, lysophosphatidylethanolamine. 
 
2.3.3 Targeted analysis of phospholipids per donor type during transplantation 
From the heat map, no obvious differences were observed in the DBD group from pre- 
to post- for all 12 lipids except for PE (34:2). All lipids were more abundant in DCD at 
pre-transplantation stage compared with DBD. All 6 PCs levels remained constant from 
pre to post in the DCD group while 2 PEs, 2 LysoPEs and 2 LysoPCs showed lower 
concentration at post- transplant stage. 
12 lipids were reanalysed from the semi-quantified data for univariate analysis. The 




lysophosphatidylcholines showed significant differences at pre- transplantation stage 
(q=0.002 and q=0.003 respectively) between the two donor groups. Figure 2.4 shows 
the amounts for LysoPC (16:0) and LysoPC (18:0), Figure 2.4a and b respectively 






Figure 2.4. Bean-plots showing variation in 2 lysophosphocholines among DBD and DCD at the pre-
transplantation stage. a) LysoPC (16:0); b) LysoPC (18:0). Mann-Whitney 2-sided, ** is q<0.01, q 
value is p value adjusted by Benjamini- Hochberg FDR correction DCD, donation after circulatory death; 
DBD, donation after brain death; LysoPC, lysophosphatidylcholine. 
 
2.3.4 Correlation of selected lysophospholipids to clinical data 
The distribution of 2 lysophosphatidylcholines in EAD (n=15) and IGF (n=41) groups 
was investigated. The Mann-Whitney test illustrated that the amount of LysoPC (16:0) 
and LysoPC (18:0) at pre-transplant were significantly higher in the EAD group 
(p=0.013 and p=0.03 respectively) (Figure 2.5a and b). The prediction ability of 
LysoPCs (LysoPC (16:0) and LysoPC (18:0)) and clinical parameters (donor AST, 




(ROC) curve. The area under the curve (AUC) for LysoPCs group was 0.91 
(accuracy=0.82, sensitivity=0.67, specificity=0.86). For comparison, the AUC for three 
pre-transplant clinical parameters was 0.63 (accuracy=0.68, sensitivity=0.33, 







  AUC  Accuracy  Sensitivity  Specificity
 LysoPC (16:0)+LysoPC (18:0)  0.91  0.82  0.67  0.86
 Donor AST+age+steatosis  0.63  0.68  0.33  0.77
 LysoPC (16:0)  0.83  0.75  0.33  0.86
 LysoPC (18:0)  0.85  0.75  0.33  0.86
 
Figure 2.5. Two LysoPCs amounts, a) LysoPC (16:0) and b) LysoPC (18:0), showing significant 
differences between EAD (n=15) and IGF (n=41) groups; c) ROC curve prediction of EAD based on 
two LysoPCs and three donor clinical parameters. Mann-Whitney 2-sided, * is p<0.05; LysoPC, 
lysophosphatidylcholine; EAD, early allograft dysfunction; IGF, immediate graft function. 
 
The effect of the two-selected pre-transplant lysophosphatidylcholines levels on 
biomedical parameters including AST, bilirubin, and creatinine levels within 14-day 
post-transplant was examined by mixed-effects maximum likelihood regression 




combination of one biomedical parameter and one lipid in each model adjusted for age 
and gender. Fitting was deemed adequate for all 6 models (p<0.0001 from chi-square 
test). After the multiple comparison correction, significant associations were observed 
between longitudinal changes in AST concentration (slope) and LysoPC (16:0) levels 
(LysoPC (16:0)×day interaction (q<0.05)), and between longitudinal changes in AST 
concentration (slope) and LysoPC (18:0) levels (LysoPC (18:0)×day interaction 
(q<0.05)). For instance, with every standard deviation (SD) increase in LysoPC 
(16:0)×day interaction, recipients’ AST levels, on average, decreased 0.017 IU/L (with 
95% confidence interval subscripts: LysoPC (16:0)×day interaction: -0.032-0.017-0.003 
p=0.006). The model parameters are listed in Table 2.3 and the effects of LysoPCs 
concentrations on AST levels are present in Figure 2.6. 
Table 2.3 Summary of mixed-effects models between AST concentration and LysoPCs level, day, 
interaction of LysoPC level and day. 




LysoPC (16:0) 0.122 -0.068, 0.313 0.21 
day -0.0003 -0.016, 0.015 0.97 
LysoPC (16:0) × day -0.017 -0.032, -0.003 0.006 
Model 2 
LysoPC (18:0) 0.117 -0.073, -0.308 0.229 
day -0.0003 -0.016, 0.015 0.965 
LysoPC (18:0) × day -0.02 -0.035, -0.005 0.007 
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Figure 2.6. Correlation of two pre-transplant lysophospholipids level and post-transplant AST, 
bilirubin and creatinine during 14-day period in mixed-effects model. a) Correlation of LysoPC (16:0) 
and AST over 14-day; b) Correlation of LysoPC (18:0) and AST over 14-day. LysoPC, 







The urgent need for specific molecular markers of hepatic tissue quality has given rise 
to small molecule phenotyping studies investigating a range of liver pathologies [2, 55]. 
The study reported here is the first study to distinguish lipid profiles between two 
different liver-donor types, with correlations to clinical outcomes related with liver graft 
dysfunction and clinical follow-up. Matched liver tissue biopsies were obtained at both 
pre- and post-transplantation stages from two types of donors, viz. DBD and DCD. 
DBD livers may suffer inflammatory changes in relation to brain death and ITU 
management and undergo a significant period of cold preservation following retrieval. 
DCD donors have no diagnosis of brain death; however, livers from DCD undergo an 
additional period of warm ischaemia prior to retrieval. This ischaemia period has been 
previously associated with increased rates of graft failure and associated with both short 
and long-term complications following transplantation [347]. A substantial number of 
DCD organs are thus discarded because of the lack of precise assays to evaluate 
transplant outcomes.  
Inflammatory responses in donor liver biopsies are donor-type specific, DBD tissue 
showed elevated levels of pro-inflammatory changes at the pre-transplantation stage. 
This was attributed to inflammatory events associated with brain death in the donors 
[54]. Following reperfusion, DBD tissue showed high levels of neutrophil infiltration and 
deposition of activated platelets. On the other hand, DCD allografts demonstrated lower 
inflammatory response but higher cell death rates that correlated with the length of 
warm ischaemia [54, 360]. Since increasing cell death was observed in DCD, we 




By focusing on donor-type using lipidomics for discovery, we identified 12 lipids 
differentiating among DBD and DCD. Trends were illustrated in the heat-map (Figure 
2.3) for the lipid median values in pre- and post- transplantation across the two donor 
types. This panel of lipids did not change from pre- to post-transplant in the same donor 
type, implying that lipid changes observed at pre-transplantation are likely to be related 
to ischaemia damage rather than reperfusion effects.  
PCs were more abundant in DCD at both transplant stages. Phosphatidylcholines have 
been associated with inflammation [361]. However, contradictory data shows that these 
lipids have a protective function as studies have linked them to regeneration processes 
in the liver [362-364].  
12 lipids were measured again, and univariate analysis was applied. Lipids with 
statistical significance when comparing DBD and DCD in both pre- and post-transplant 
biopsies were LysoPC (16:0) (q<0.01) and LysoPC (18:0) (q<0.01) showing higher 
values in DCD (Figure 2.4).  
LysoPCs are lysophospholipids generated from PCs (Figure 2.7) via the action of 
phospholipase A2, and like other lysophospholipids they are likely to be activators or 
inhibitors of G-protein coupled receptors (GPCRs) [365].  Phospholipase A2 synthesises 
lysophospholipids including both lysoPCs and lysoPEs from PEs and PCs by producing 






Figure 2.7. Lipid metabolism in the healthy liver, showing endogenous metabolism of triacylglycerol 
(TAG) and phospholipids. Phosphatidic acid (PA) is generated in vivo by catabolic modification of 
glycerol-3-phosphate. Diacylglycerol (DAG) is a key metabolic intermediate and intracellular signalling 
molecule which can be converted to TAGs by the action of DAG acyltransferases to glycerophospholipids 
including phosphatidylcholines (PC), phosphatidylethanolamines (PE) and ultimately to 
lysophosphatidylcholines (LysoPC), lysophosphatidylethanolamines (LysoPE) by the action of 






In DCD donors, LysoPCs were found to be increased. LysoPCs are known to be 
precursors of the platelet-activating factor (PAF), a potent phospholipid inflammatory, 
which has been previously associated with both hepatic ischaemia and reperfusion 
injury (IRI) [366-368]. Hence, DCD donors might be prone to the PAF mediated 
inflammatory pathway before transplantation (pathway illustrated in Figure 2.7).  
The in-vivo function of LysoPCs and in particular their role in intracellular signalling is 
mostly unknown. LysoPCs have previously been associated with inflammatory liver 
disease [369, 370]. Interestingly Cortes et al. [55] found in a study where all donors were 
from DBD that LysoPC (16:0) and LysoPC (18:0) were higher in grafts that presented 
EAD p<0.05, supporting the hypothesis that these lysophospholipids affect transplant 
outcomes.  
To understand the relevance of the two lipids to transplantation we investigated EAD. 
EAD is a clinical term which can reflect donor, recipient and transplant characteristics, 
and it can be utilized as a transplant benchmark [371]. The incidence of EAD in our 
study was 26%, this was in the upper range of known values for incidence ranging from 
14% to 27% [372]. LysoPC (16:0) and LysoPC (18:0) showed (p<0.05) significant 
difference when their contents between EAD and IGF groups were compared. The 
ROC curve of these two LysoPCs versus three clinical parameters known to be risk 
factors of EAD indicated that LysoPC (16:0) and LysoPC (18 :0) were better at 
prediction of EAD, in particular, accuracy increased from 68% for AST, age and 
steatosis to 82% for LysoPCs. A limitation of this comparison is that it was applied to 
compare donors only at pre-transplantation; however it is known that EAD is affected 




The regression between AST 14-day concentrations and two LysoPCs indicated that 
LysoPCs levels at pre-transplant were associated with AST concentration at post-
transplant. Since AST is considered an indicator of liver injury, the association between 
high AST post-transplantation and LysoPCs pre-transplantation warrants further 






In conclusion, the analysis of phospholipids in the context of liver transplantation has 
identified two lipids differentiated in DBD and DCD livers. LysoPC (16:0) and LysoPC 
(18:0) could have a role as intermediates in signalling tissue damage due to warm 
ischaemia. This study is relevant in identifying pre-transplant biomarkers for tissue 
quality and in designing appropriate therapeutic strategies in order to minimize damage 
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The named researchers below contributed to this chapter by conducting the following 
experiments. 
1. Mr Wayel Jassem (King’s College Hospital, UK): Biopsies collection and 
clinical data collection. 
2. Mr Parthi Srinivasan (King’s College Hospital, UK): Biopsies collection. 






In recent decades, the prevalence of end stage liver diseases has greatly increased due to 
factors such as alcohol abuse, unhealthy lifestyle and microbiome disturbance [374]. As 
a result, the increasing demands for suitable organ donors for liver transplantation 
exceed the number of donors, which has remained largely static [375]. The worsening 
organ shortage is reflected in the median time to transplant in wait-listed adult patients. 
In the United States median time increased from 14.8 months in 2004 to 19.5 months 
in 2011. As such, transplant centres and allocation organizations have attempted to 
expand the pool of acceptable donors, including the use of DCD donors [376]. Although 
some centres have reported satisfactory results by using DCD allografts, other data 
indicates that recipients of controlled DCD liver allografts have an increased incidence 
of graft dysfunction, early graft loss and cholangiopathy as compared to recipients of 
DBD livers [377-381]. 
The pathophysiology of cardiac death is markedly different from that of brain death. As 
compared to livers obtained from DBD, in which there is no consistent proceeding 
cardiac arrest, DCD livers are subjected to additional hypoxic insult. However, brain 
death generates an inflammatory response with the release of various pro-inflammatory 
mediators, leading to upregulated expression of adhesion molecules on vascular 
endothelium and subsequent leukocyte tissue infiltration [22, 382, 383]. Jassem et al. 
demonstrated that prior to transplantation DCD allografts have lower expression of 
ICAM-1, potentially suggesting less allograft inflammation [384].  
Liver ischaemia reperfusion injury (IRI) is the injury caused by the ischaemia and 




sustained during the cold preservation after liver retrieval and during warm reperfusion 
at implantation in recipients. IRI is associated with the release of reactive oxygen species 
and pro-inflammatory mediators [385]. Studies revealed that sphingolipids metabolites 
regulate a diverse range of cellular processes that are important in inflammatory 
disorders and hepatic insulin resistance [85, 386]. Among several types of sphingolipids, 
the ceramide pathway is of interest as it is associated with inflammatory response and it 
is also widely distributed in mammalian tissue [387]. Elevated levels of ceramides 
promote inflammation and downstream apoptosis by enhancing susceptibility to 
palmitate-induced cell death [85, 388, 389]. The role of ceramides has yet to be 
described in human liver transplantation [85] despite previous observations of ischaemia 
reperfusion-induced accumulation of ceramides in various organs, including the liver 
[388, 389].  
In this study, ceramide contents were assessed to examine the IRI in biopsies obtained 






3.2.1 Patient sampling  
Overall 46 Tru-Cut tissue biopsies were obtained from liver allografts pre- and post-
transplantation. The first (pre-transplant) biopsy was taken at the end of cold 
preservation, prior to implantation, and the second (post-transplant) biopsy was 
obtained approximately 1 hour after graft reperfusion. A separate biopsy was obtained 
for histopathological evaluation of donor steatosis. Biopsies were immediately snap-
frozen in liquid nitrogen and stored at -80°C until extraction for LC-MS analysis. In all 
procedures, liver allografts were flash-cooled and perfused with University of Wisconsin 
preservation fluids until the time of transplantation. This study received prior approval 
from the ethics committee at King’s College Hospital.  
The study included 2 types of adult donors: DBD (n=10) and DCD (n=13). A wide 
spectrum of donor clinical data was collected for comparison among groups and for 
correlation with lipid level. In the DBD group, 2 of the livers had mild steatosis (up to 
30% fat on biopsies), 3 had moderate steatosis (30–60% fat) and the remaining DBD 
grafts had none.  In the DCD group, 4 allografts were mildly steatotic, and the remainder 
were normal. In the DCD group, functional warm ischaemia time (WIT) was calculated 
from the time when systolic blood pressure was below 50 mmHg to the time of organ 
retrieval. The relevant donor data are included in Table 3.1.  
All recipients were patients with stable chronic liver disease who did not require 
hospitalization prior to transplantation. Indications of liver transplantation in the study 
include alcoholic liver disease (ALD), primary sclerosing cholangitis (PSC), hepatic C 




transplantation, all patients received immunosuppressive therapy with tacrolimus and 
prednisolone. Recipients’ 14-day period of international normalized ratio (INR), 
aspartate aminotransferase (AST), albumin, gamma-glutamyl transferase (GGT), 
bilirubin, alkaline phosphatase (ALP) and creatinine level were recorded. Graft 
performance was assessed based on level of AST, INR and bilirubin level after 
transplantation.  The relevant recipient details are listed in Table 3.2. 
 
3.2.2 Sample preparation and analysis 
For all 46 biopsies, identical lipidomics procedures for sample preparation and negative 
LC-MS/MS analysis were executed. Sample preparation prior to analysis followed 
description in Chapter 2.2.5.  
 
3.2.3 Ceramides analysis  
The identification of ceramides Cer16, Cer18, Cer20, Cer22 and Cer24 (with the 
number suffix denoting the length of the acyl chain) was achieved by structure and 
fragmentation patterns comparison of the MS2 data in databases, literature and C8 
standard [244, 321, 357, 390]. Five ceramides were measured in the LC-MS data using 
Waters MassLynx software (Waters Corporation, Milford, MA) and their peak area 
ratios to internal standard were calculated. Mean ratio values were used to plot the heat-
map using an open source ‘R’ package, 'gplots' [358]. Subsequently univariate non-




ceramide level in each group at pre- and post-transplantation stage, as well as between 
DBD and DCD at both stages.  
Spearman’s correlation analysis was applied separately in DCD and DBD groups to 
investigate the correlation of ceramides at both pre- and post-transplant with recipients’ 
14-day clinical data including INR, GGT, AST, ALP, ALB, Bilirubin, creatinine and 
donors’ age, gender, ITU stay, inotrope support, WIT, CIT. All obtained p values were 
adjusted for multiple comparisons using Benjamini- Hochberg correction to control the 
false discovery rate (FDR) [328]. All statistical calculations were conducted in SPSS 22 
(IBM: Armonk, United States). Orthogonal projections to latent structures-
discriminant analysis (OPLS-DA, SIMCA 13.0.2, Umetrics, Sweden) was used for 
multivariate analysis using the 5 ceramides as variables. Two models were investigated, 
DBD vs. DCD (n=46), and DBD vs. DCD for liver biopsies from non-steatosis (n=28). 
Details of the analytical workflow are provided in the Figure 3.1. 
1
5 CERAMIDES ANALYSIS           
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(for all and non-steatotic biopsies)
 
Figure 3.1. Analytical workflow for five ceramides. DBD, donation after brain death; DCD, donation 




3.3 Results and discussion 
3.3.1 Clinical outcomes 
No significant differences were observed in all parameters listed in Table 3.1 and Table 
3.2 when comparing DBD with DCD. DCD livers underwent an additional total WIT 
of 72±18 min (average ± SD) in 13 donors, although 21% shorter average CIT were 
found in DCD.  







DBD vs DCD 
Age(years) 51(19) 54(13) 0.69 



















GGT (IU/L) [a] 35(14) 28(19) 0.73 
AST (IU/L) [a] 39(6) 70(53) 1 
Bilirubin (μmol/L) [a] 14(13) 8(4) 0.79 
ITU stay (days) 5(9) 2(2) NA 
Inotrop support (Y/N) 7/3 9/4 NA 
Functional WIT (min)  20(7)  
Hepatectomy time (min)  27(10)  
Bench perfusion (min)  26(12) NA 
Total WIT (min)  72(18)  
CIT (min) 496(212) 389(117) 0.60 
DBD, donation after brain death; DCD, donation after circulatory death; GGT, gamma-glutamyl 
transferase; AST, aspartate aminotransferase; ITU, intensive treatment unit; WIT, warm ischaemia time; 
CIT, cold ischaemia time; NA, not applicable. Continuous values are expressed as means (standard 
deviation). Total WIT is the sum of Functional WIT, Hepatectomy time and Bench perfusion. [a] Tested 












DBD vs DCD 
Age (years) 42(13) 57(6) 0.56 
Gender (female/male) 7/3 4/9 0.10 
BMI (kg/m2) 24(4) 26(5) 0.34 
MELD Score (median) 12 13 1.0 
Alcoholic liver disease (ALD) 2 9  
Primary sclerosing cholangitis (PSC) 2 0  
Hepatic C virus (HCV) 1 5 NA 
Hepatocellular carcinoma (HCC) 0 2  
Biliary atresia (BA) 0 0  
Others 5 1  
AST (IU/L) [a] 963(611) 2356(2714) 0.17 
Bilirubin day 5 (μmol/L)  80(74) 74(70) 0.92 
INR day 2 1.43(0.16) 1.51(0.46) 0.65 
DBD, donation after brain death; DCD, donation after circulatory death; BMI, body mass index; MELD, 
model for end-stage liver disease; ALD, alcoholic liver disease; PSC, primary sclerosing cholangitis; HCV, 
hepatitis C virus; HCC, hepatocellular carcinoma; BA, biliary atresia; AST, aspartate aminotransferase; 
INR, international normalized ratio; NA, not applicable. [a] Tested on the day of operation, [b] Mann 
Whitney test (2-sided) or Fisher exact test (2-sided). 
 
 
3.3.2 Ceramide identification 
There are two production pathways for ceramides (Figure 3.2). De novo ceramide 
synthesis is achieved with the participation of ceramide synthases (CerS). Apart from 
this, ceramides are also produced by sphingolipids recycling pathway [388]. Based on 
the exploration of ceramide synthases (CerS) distribution by northern blot, some groups 




CerS4 (20%) and CerS5 (5%) [388, 391].  It is also found that short chain ceramides 
with fatty acyl chains contain fewer than 12 carbons are served as detergents as they 
can easily disperse in water. Ceramides with long fatty acyl chains of 16-28 carbons are 
more common in mammalian cellular membranes [392]. Of these ceramide syntheses, 
CerS2 and CerS4 mainly synthesize C20:0, C22:0, C24:1, C24:0, C26:1 and C26:0 


















Figure 3.2. Ceramide synthesis pathways in hepatocyte. ER, endoplasmic reticulum; Cer, ceramide; 
CERT, ceramide transfer protein; SM, sphingomyelin; SMase, sphingomyelinase. Figure conceptualised 
from the linkage of sphingolipids and inflammatory disease[85]. 
 
Ceramides were identified based on suggested fragmentation patterns and comparison 
with a standard Ceramide (d18:1/8:0) [390]. The speculative structures of two daughter 
ions (m/z 168.18 and 237.28) are listed in Figure 3.3. The chromatogram and spectra 
(both channel 1 and channel 2) of the Cer8 were shown below in Figure 3.4. The two 





After the study of possible fragments of the standard, an example of Cer24 fragmentation 
is illustrated in Figure 3.5. The expected two fragments were observed as in highlighted 
red circle. Table 3.3 contains the relevant analytical data for the ceramide analysis (list 
of mass-to-charge ratio or m/z values, the observed ions, main fragments and the 
instrumental variation of the measurements in quality control samples).  
As shown in the spectra of Cer8, the most abundant ion was in the format of [M-H]-, 
while [M+FA-H]- was the main parent ion in Cer24. The fragmentation pattern 
difference might be caused by the side chain length in these two ceramides. However, 
the [M+FA-H]- was found to be the main parent ion in all five ceramides included in 
this study. 
Table 3.3. Identification of markers based on molecular weight, retention time and collision induced 
dissociation fragmentation of lipids. 
m/z Identified as Observed ion Fragments 
RSD (%) 
QC 
582.51 Cer (d18:1/16:0)/Cer16 [M+FA-H]- 237, 280 22.9 
610.54 Cer (d18:1/18:0)/Cer18 [M+FA-H]- 237, 308 14.3 
638.57 Cer (d18:1/20:0)/Cer20 [M+FA-H]- 237, 336 19.1 
666.60 Cer (d18:1/22:0)/Cer22 [M+FA-H]- 237, 364 4.93 





























Figure 3.4. The chromatogram and spectra of the Cer8 standard. (a) Chromatogram of C8 ceramide 
standard, (b) Channel 1 MS spectrum of C8 ceramide showing two main parent ions, (c) Channel 2 









Figure 3.5. The chromatogram and spectra of the Cer24 in a QC sample. (a) Chromatogram of C24 
ceramide, (b) Channel 1 MS spectrum of C24 ceramide showing two main parent ions, (c) Channel 2 
MS spectrum of C24 ceramide with daughter ions. 
 
 
3.3.3 Univariate analysis for ceramides per donor type during transplant 
The amounts for the 5 selected ceramides were measured and plotted in a heat-map 




differences were observed for all five ceramides, and the same result applies to DBD-
post and DCD-post.   
To assess the impact of ischaemia injury, ceramide levels in all 46 biopsies were 
compared between pre- and post-transplantation within each donor group. The analysis 
showed that significant difference was observed in regard to ceramides level from pre- 
to post-transplantation. Overall changes in DBD from pre- to post transplantation for 
C18, C20, C24 (p<0.05) were significant and C22 (p<0.05) were more pronounced for 






Figure 3.6. Heat-map showing distinct ceramides profiles of DBD and DCD tissue in 46 transplant 
samples. Values are mean amounts per donor group at pre and post-transplantation stages. A clustering 




Ceramides are at present well known markers of inflammation and elevated ceramide 
level are thought to produce inflammation and downstream apoptosis by enhancing 
susceptibility to palmitate-induced cell death [85]. In I/R injury, accumulation of 
ceramides was observed in organ tissues, however it is not yet known how the size of a 
ceramide determines inflammation response [388, 389]. In-vitro experiments showed 
that elevated level of C16-ceramide resulted in TNF-α-induced hepatocyte apoptosis 
[393]. Conversely elevated de-novo C18-ceramide, synthesised by CerS4 in the liver, 
was also found to function as a powerful pro-apoptotic activator in tumour cells [386, 
391]. Bigger ceramides also called very long chain ceramides (C24-ceramides) are 
thought to be the most abundant in healthy liver and their decrease can in turn indicate 
liver pathology [394]. As illustrated in Figure 3.2, After being generated by 
enhancement of de novo biosynthesis or sphingolipid recycling, ceramide can then 
signal to trigger the Nlrp3 inflammasome. The stimulation of which promotes the 
activation of caspase 1, leading to pyroptosis, a highly inflammatory form of 
programmed cell death [395]. 
These results are in line with what was expected from IR response, increased long chain 
(C18-C20) and decreased very long chain (C24) suggesting higher inflammation at 
post-transplant stage. C22 increased its level after graft implantation; this is not in 






3.3.4 Correlation of ceramides to clinical data 
Spearman’s rank correlation analysis was applied separately in DCD and DBD groups 
to investigate the correlation of ceramides at both pre and post-transplant with recipients’ 
14-day clinical data. According to the correlation result, creatinine, INR, bilirubin, 
donor age and WIT show high significance, then Benjamini- Hochberg false discovery 
correction was used to test the p value of those 5 parameters. After the p-value 
correction, Cer18 showed significant correlation to bilirubin and INR at pre-
transplantation, creatinine at post-transplantation in DCD, while no significant 
correlation reflects in DBD group at both pre and post-transplantation (see details in 
Table 3.4). 





Corr. coefficient q value Corr. coefficient q value 
BIL 3 0.7747** 0.0031 INR 2 0.7785** 0.0017 
BIL 9 0.8182** 0.0011 INR 4 0.7565** 0.0028 
BIL 10 0.8252** 0.0010 INR 8 0.8421*** 0.0006 
BIL 11 0.9423*** 0.00005 CREAT 9 0.8476*** 0.0005 
BIL 12 0.9000*** 0.0009 CREAT 10 0.8476*** 0.0005 
BIL 13 0.9643*** 0.0005    
Spearman correlations and Benjamini-Hochberg correction was applied. **q<0.01, ***q<0.001. DCD, 
donation after circulatory death; DBD, donation after brain death; BIL, bilirubin; INR, international ratio; 
CREAT, creatinine. 
 
Lang et al. found that bilirubin induces ceramide formation [396], which explains the 
high correlation of bilirubin and Cer18 at DCD pre-transplant stage in our study. 




398], the higher Cer18 level in DCD at pre-transplant stage compared with DBD 
indicates that severe apoptosis took place in DCD hepatocytes. INR, the assessment 
parameter for coagulation monitoring [399], indicated the liver injury when its value is 
elevated, hence, the correlation of INR with Cer18 in DCD post-transplant 
demonstrates ischaemia reperfusion injury in DCD. 
The association between C18-ceramide and serum level of creatinine is of interest as 
renal dysfunction post-transplant has been seen to occur at higher rate in liver 





This study explored five widely distributed ceramide levels (Cer16, Cer18, Cer20, 
Cer22 and Cer24) in 46 biopsies from two different donor groups, DBD and DCD, at 
both pre- and post-transplantation stages. It was discovered that ceramide levels differ 
in DBD and DCD, as well at two transplantation stages suggesting that the ceramide-
mediated inflammation response was more severe in DBD. Correlation between 
ceramides with clinical outcomes revealed that ischaemia reperfusion injury in DCD is 
related with enzymes and clinical index. In conclusion, ischaemia reperfusion injury 
involved during liver transplantation in DBD and DCD impacts the levels and trends of 




 Purines associated with liver tissue 





The named researchers below contributed to this chapter by conducting the following 
experiments. 
1. Mr Wayel Jassem (King’s College Hospital, UK): Biopsies collection and clinical 
data collection. 
2. Mr Parthi Srinivasan (King’s College Hospital, UK): Biopsies collection. 






There is an ever increasing demand of organs for transplantation, but the available 
organs are insufficient to meet the demand [401]. This is reflected by the static number 
of people registered on the Organ Donor Register (ODR) in the UK which only saw a 
5% rise from 2012 to 2017 [402]. Meanwhile in the same period, the number of patients 
requiring a liver transplant increased from 452 to 519 [402]. This stark surge in the 
demand for liver transplants is attributable to the global incidence of liver diseases such 
as drug-induced hepatotoxicity [403], fatty liver diseases [404], cirrhosis [405] and 
hepatitis infections, primarily caused by hepatitis B and C virus [406, 407].  
To safeguard patients, pre-transplant donor screening is used to determine the plausible 
success rate of liver transplants. The optimal/sub-optimal criteria for liver donors 
including age (<50 years/>50 years), weight (<100kg/>100kg), intensive care stay (<5 
days/>5 days), functional warm ischaemic time (<20 mins/>20mins, <30mins), cold 
ischaemia time (<8 hours/>8 hours, <12 hours) and steatosis (<10%/>15%) [19]. This 
has resulted in up to 20% of donation after brain death (DBD) organs not meeting the 
strict clinical criteria [408] and a 78% increase in the discard rate of donation after 
circulatory (DCD) livers [409]. This has potentially led to a number of otherwise 
transplantable organs being discarded [410]. Therefore, the need to identify more 
specific pre-transplantation markers of liver damage is a priority in order to expand the 
pool of transplantable livers.  
Currently, liver function tests are the standard assessment in establishing liver 
dysfunction, as evaluated by elevated concentrations of liver-enzymes such as alkaline 




and gamma-glutamyl transferase (GGT) [411, 412]. However, such tests lack 
sensitivity and specificity and can be affected by patient factors such as genetics, 
medicines and other non-associated diseases [413-416]. Thus far, transcriptomics and 
genomics have been used to discover biomarkers in liver pathophysiology [417]. It has 
been postulated in experimental studies that an association exists between brain death 
and an increased inflammatory response in DBD livers leading to early allograft 
dysfunction (EAD). There is no clear evidence of brain death itself entailing a systemic 
inflammatory response, but the adenine-monophosphate (AMP) pathway has been 
highlighted in inflammation [418]. Furthermore, the association of the AMP pathway 
to immediate graft function (IGF) has not been studied previously [419, 420]. 
In Chapter 2, two Lysophosphatidylcholines, were found to be differentiated in DBD 
and DCD groups at pre- transplantation stages, as well as increased in EAD. The 
objective of this study was to employ hydrophilic interaction chromatography-mass 
spectrometry (HILIC-MS) technique to investigate polar metabolites at both pre- and 
post-transplantation, in hepatic tissue in two distinct donor types: viz. DBD and DCD; 
the latter undergoing warm ischaemia events. Following this, I wanted to ask whether 
metabolites that were different between donor types were associated to clinical 





























Figure 4.1. Study workflow. PCA, principal component analysis; OPLS-DA, orthogonal projections to 
latent structures-discriminant analysis; EAD; early allograft dysfunction; IGF, immediate graft function; 






4.2.1 Chemicals and reagents  
All solvents, water, methanol, acetonitrile, formic acid and methyl tertiary butyl ether 
(MTBE), were liquid chromatography–mass spectrometry (LC-MS) grade purchased 
from Sigma-Aldrich. Two internal standards, L-serine13C315N (95%) and L-
valine13C315N (95%) for hydrophilic liquid interaction chromatography (HILIC) were 
purchased from Sigma-Aldrich. In-vial dual extractions were performed in amber glass 
high performance liquid chromatography (HPLC) vials with fixed 0.4 mL inserts 
(Chromacol: Welwyn Garden City, UK). 
 
4.2.2 Patients and samples 
All patients and samples information were stated in Chapter 2.2.2, 2.2.3 and 2.2.4. 
Following the transfer of organic phase from extracted sample for lipidomic analysis 
(Chapter 2.2.5), 100 µl the lower aqueous phase from all samples were also transferred 
to clean vials for further sample preparation. To this, 10ul methanol: water (4:1) solution 
containing 1mmol/ml internal standards (L-serine13C315N and L-valine13C315N) were 
added. After being vortexing for 10 mins at room temperature, samples were centrifuged 
at 3000g for 30 min at 4 ºC. Same procedures were applied to quality controls which 





4.2.3 Chromatographic and spectrometric conditions 
Samples were kept in the chamber with targeted temperature of 4 °C, and the injection 
volume is 5 µl with full loop function (20 µl loop size). Chromatographic separation for 
HILIC analysis was achieved using a Merck Sequant ZIC-HILIC column (150mm × 
4.6mm, 5 μm) coupled to a Merck Sequant ZIC-HILIC guard column (20mm × 
2.1mm), maintained at room temperature.  A gradient was employed consisting of 0.1% 
formic acid in water (mobile phase A) and 0.1% formic acid in acetonitrile (mobile phase 
B).  The solvent was delivered at a flow rate of 0.3 mL/min.  The gradient started at 80% 
mobile phase B, followed by a linear reduction to 20% mobile phase B after 30 minutes, 
initial conditions were restored at 30.1min to allow 9.9 minutes of column re-
equilibration. The mass spectrometer (Xevo-QTOF) was operated in positive ion mode, 
and a capillary voltage of 3.2 kV and a cone voltage of 35 V were used. The desolvation 
gas flow was 500 L/hour and the source temperature was 120°C. All analyses were 
acquired using the lock spray to ensure accuracy and reproducibility; leucine enkephalin 
was used as lock mass (m/z 556.2771 and 278.1141) at a concentration of 200 ng/mL 
and a flow rate of 10 μL/min. Data were collected in the centroid mode over the mass 
range m/z 50–1000 with an acquisition time of 0.1 seconds a scan. QCs were run in 
between every 8 samples in random orders. 
 
4.2.4 Multivariate analysis 
All data was processed within ‘XCMS’ package in ‘R Studio’ (version 1.0.153), the 
multivariate analyses were conducted in both ‘R Studio’ and ‘SIMCA’ (version 14, 




transplant matched samples n=94 (DBD n=70, DCD n=24) and 17 QCs. Principal 
component analysis (PCA) was carried out to detect outlier(s) and to examine the 
distribution of QCs.  
All pre- transplant data was then divided into training dataset (DBD n=30, DCD n=5) 
and test dataset (DBD n=5, DCD n=7). Orthogonal projections to latent structures-
discriminant analysis (OPLS-DA) model was built based on the training dataset to 
examine the profiling of pre- transplant samples in DBD and DCD groups. Test dataset 
was utilised to assess the prediction ability of the built model. S-plot derived from the 
OPLS-DA model was then applied to select features based on covariance p[1] and 
correlation p(corr) value (p[1]>0.1, p(corr)>0.4 and p[1]<-0.1, p(corr)<-0.4).  
 
4.2.5 Univariate analysis 
Selected features were measured in the LC-MS data using Waters MassLynx software 
(Waters Corporation, Milford, MA). Feature concentrations were expressed as ratios of 
lipid peak areas to internal standard peak area. The identification (level 2 confidence) 
was performed by using metabolites mass to search against in-house and public 
metabolite databases [244, 321, 357], their structure and fragmentation patterns in the 
MS2 data were also studied by comparing with databases to aid the annotation. 
Feature levels between DBD and DCD as well as between EAD and IGF groups at pre- 
and post-transplantation stage were examined with univariate non-parametric Mann-
Whitney test (2-sided) and Benjamini-Hochberg test to control the false discovery rate 




features (AST, Bilirubin, GGT) were conducted. Calculations were conducted in SPSS 
23 (IBM: Armonk, United States). Figures were plotted in GraphPad Prism 6 





4.3.1 Clinical outcomes 
Patients details on all 94 samples including comparisons on the clinical variables 
between the groups are represented in Table 4.1. There were no significant differences 
between DBD and DCD groups in donors’ ages, EAD/ IGF distribution, liver enzymes, 
hepatic steatosis or serum bilirubin levels. Differences were observed in the recipients’ 
ages (p<0.05) between these two groups. 
Table 4.1. Demographic characteristics and clinical data for 94 subjects involved in this study. 
Donor DBD (N=35) DCD (N=12) p-value[b] 
Age(years) 53(18-82) 56(35-76) 0.526 
Gender(female/male) 19/16 6/6 1 
Hepatic 
steatosis 
No 14 7  
Mild (<30%) 18 3 0.305 
Moderate (30-60%) 3 2  
GGT (IU/L) [a] 52(6-208) 92(21-315) 0.342 
AST (IU/L) [a] 85(22-517) 161(15-392) 0.139 
Bilirubin (μmol/L) [a] 11(3-37) 12(4-26) 0.695 
ITU stay (days) 4(1-28) 4(1-10) 0.168 
Inotrop support (Y/N) 19/16 6/6 1 
Functional WIT (min)  21(9-33)  
Hepatectomy time (min)  31(13-57)  
Bench perfusion (min) NA 28(10-44) NA 
Total WIT (min)  79(46-100)  
CIT (min) 504(210-840) 457(270-720) 0.212 
Recipient DBD (N=35) DCD (N=12) p-value[b] 
Age (years) 44(20-65) 54(46-70) 0.029 
Gender (female/male) 13/22 5/7 1 
BMI (kg/m2) 25.8(18.4-34.6) 27.3(22.1-35.8) 0.277 

























AST (IU/L) [a] 480(10-7485) 613(18-5307) 0.494 
Bilirubin day 7 (μmol/L) 56(7-258) 52(12-103) 0.772 
INR day 7 1.04(0.85-1.21) 1.06(0.92-1.3) 0.909 
EAD/IGF 6/29 4/8 0.251 
DBD, donation after brain death; DCD, donation after circulatory death; GGT, gamma-glutamyl 
transferase; AST, aspartate aminotransferase; ITU, intensive therapy unit; WIT, warm ischaemia time; 
CIT, cold ischaemia time; BMI, body mass index; MELD, model for end-stage liver disease; ALD, 
alcoholic liver disease; PSC, primary sclerosing cholangitis; HCV, hepatitis C virus; HCC, hepatocellular 
carcinoma; BA, biliary atresia; EAD, early allograft dysfunction; IGF, immediate graft function. 
Continuous values are expressed as means (minimum-maximum); NA, not applicable. Total WIT is the 
sum of Functional WIT, Hepatectomy time and Bench perfusion. [a] Tested on the day of operation, [b] 
Mann Whitney test (2-sided) or Fisher exact test (2-sided). 
 
4.3.2 Multivariate model and feature selection 
The unit variance (UV) scaled dataset was first inspected for detection of outlier(s). In 
Figure 4.2, PCA score plot and observation diagnostic plot (observations exceed both 
score distance and orthogonal distance are strong outliers, as located in the top right area 
of the plot) showed one strong outlier, sample 2_DCD_post_24, and was removed. After 
excluding the outlier, no obvious outlier was discovered as shown in Figure 4.3. After 
the removal of one outlier, the distribution of QCs and samples were investigated. As 
can be seen in Figure 4.4, QCs clustered near the origin in the PCA plot (R2X=0.391, 
Q2=0.361).  
To follow this, comparison between DBD and DCD samples at pre-transplant was 
performed.  An OPLS-DA model was built with training dataset (DBD n=30, DCD 
n=5), and the model was tested with the test dataset (DBD n=5, DCD n=7). As shown 
in the misclassification table, test samples in DBD group can be predicted with 100% 







Figure 4.2. PCA summary plots based on 96 samples. a) shows variance explained by each principal 
component; b) is a diagnostic plot showing the distance of observations orthogonal to the projection plane 
and the distance of observation projections to the regular/majority data; c) is a score plot, strong outliers 
can be seen if they are outside the Hotelling’s T2 circle; d) shows a loading plot showing which metabolic 




Figure 4.3. PCA summary plots based on 95 samples. a) is a variance plot; b) is a diagnostic plot showing 





Figure 4.4. PCA plot summarised the distribution of QCs and samples. QCs were represented as 
yellow circles, and samples were represented as blue circles. 
 










 DBD DCD Accuracy 
DBD 5 0 100% 
DCD 1 6 85.71% 
Total 12 91.67% 
Fisher’s prob.                            0.0076 
 
In order to identify which metabolite features are the strongest discriminators between 
DBD and DCD at pre- transplant, S-plot (Figure 4.5) derived from the OPLS-DA 
model (R2X=0.519, R2Y=0.669, Q2=0.352) was then studied, 12 features were selected 
based on the criteria stated in 4.2.4. From the 12 selected features, a panel of 5 







Figure 4.5. Metabolic feature selection from the S-plot. All the dots represent detected features, and the 
pink dots were selected for annotation. 
 
Table 4.3. Annotation of markers based on molecular weight, retention time and collision induced 
dissociation fragmentation of 5 metabolites. 
Identified as m/z 
Retention time 
(min) 
Observed ion QC RSD (%) 
Adenine 
monophosphate 
348.08 17.3 [M+H] + 12.80 
Adenosine 268.10 14.2 [M+H] + 5.88 
Adenine 136.06 17.1 [M+H] + 7.16 
Hypoxanthine 137.05 9.75 [M+H] + 6.07 




4.3.3 Relative amount of the identified 5 features across groups 
From the previous section, 5 discriminating features between DBD and DCD at pre-




5 metabolites vary across all eight groups, jittered scatterplots were produced as shown 
in Figure 4.6.  
At pre-transplant stage, the level of AMP and adenine were significantly higher in the 
DBD group compared to DCD (q<0.01 and q<0.001). Contrastingly, it is observed that 
uric acid is more abundant in DCD at the pre-transplant stage compared to DBD 
(q<0.001). Additionally, the scatter plots illustrated that the amount of AMP and 
adenine were higher in the IGF group compared to EAD. The Mann-Whitney test 
confirmed that the mean levels of adenine and AMP were significantly statistically 
different between EAD and IGF (q<0.05). On the other hand, adenosine, hypoxanthine 
and uric acid showed no significant difference in the level distribution between EAD 
and IGF groups. 
At the post-transplant stage, the Mann-Whitney test revealed that the level of AMP, 
adenine (q<0.01) and Hypoxanthine (q<0.05) were significantly higher in the DBD 
group compared to DCD. On top of this, the scatter plot in Figure 4.6d and Figure 4.6e 
illustrated that the amount of hypoxanthine and uric acid were more abundant in the 
EAD group compared to IGF with statistical significance (q<0.05). However, 
interestingly, the abundance of hypoxanthine in all four groups is relatively lower 





4.3.4 ROC analysis and clinical correlation 
The prediction ability of purine metabolites and general liver function indicators at pre-
transplant were evaluated with ROC analysis. The accuracy, area under the curve 
(AUC), sensitivity and specificity for individual metabolite and enzyme in predicting 
IGF were listed in Table 4.5. Adenine and AMP both showed reliable prediction ability 













Figure 4.6. Jittered scatter plots of 5 metabolites in four groups at both transplant stages. a) AMP, b) 
Adenosine, c) Adenine, d) Hypoxanthine and e) Uris acid. AMP, adenosine monophosphate; DBD, 
donation after brain death; DCD, donation after circulatory death; IGF, immediate graft function; EAD, 
early allograft disfunction. Results represented as mean ± SD, p-value was derived from Mann-Whitney 




In order to investigate whether liver enzymes had any effects on these metabolic features, 
partial correlation analysis was employed. Five metabolites relative amount in pre- and 
post-transplant samples, together with AST, Bilirubin and GGT in donors on the day 
of operation (day 0) and in recipients on the day after operation (day 1) were included 
for correlation analyses. In Table 4.5, the only significant correlation was observed 
between hypoxanthine and bilirubin after Bonferroni correction. 
Table 4.4. ROC analysis for 5 annotated metabolites and 3 liver enzymes at pre-transplant for the 
prediction of IGF.  
 AUC Accuracy Sensitivity Specificity 
Adenine 0.74 0.52 0.45 0.78 
AMP 0.72 0.51 0.44 0.78 
Bilirubin 0.64 0.62 0.65 0.50 
GGT 0.61 0.62 0.71 0.28 
Adenosine 0.60 0.53 0.54 0.50 
AST 0.57 0.68 0.76 0.36 
Hypoxanthine 0.54 0.59 0.67 0.28 






Table 4.5. Partial correlation analysis (Pearson’s correlation with adjusting for patient age) between 
the 5 selected metabolites and liver enzymes.  p-values were represented as q-values after applying 
Bonferroni correction. *p/q<0.05, **p/q<0.01. 
Metabolites  AST Bilirubin GGT 
Adenine Coefficient -0.045 -0.122 -0.134 
p-value 0.968 0.321 0.275 
q-value 1 1 1 
Adenosine Coefficient -0.005 -0.274 -0.084 
p-value 0.967 0.024* 0.496 
q-value 1 0.072 1 
AMP Coefficient -0.009 -0.097 -0.106 
p-value 0.945 0.430 0.390 
q-value 1 1 1 
Hypoxanthine Coefficient -0.189 -0.320 -0.039 
p-value 0.122 0.008** 0.752 
q-value 0.366 0.024* 1 
Uric acid Coefficient 0.042 -0.019 0.204 
p-value 0.733 0.875 0.095 






In chapter 2, a lipidomics approach was applied to 112 liver biopsies from DBD and 
DCD at pre- and post-transplant stages. In this report, hydrophilic metabolic features in 
94 liver samples were investigated using HILIC LC-MS technique.  
By conducting multivariate PCA, the distribution of outliers and QC samples were 
examined (Figure 4.2, Figure 4.3 and Figure 4.4). One outlier was excluded, and the 
close cluster of QCs confirmed the good reproducibility of the sample preparation and 
analysis. Using OPLS-DA built with a training dataset, the accuracy of the model 
prediction was validated with the test dataset. This training-test approach prevented 
‘overfitting’ and evaluated the model with the classification accuracy.  With the test 
dataset, all the features discriminated DBD from DCD with the accuracy of 91.67%, 
which implied the reliability of the OPLS-DA model.  
The five annotated purines discovered from the OPLS-DA model are generated from 
the purine metabolism pathway. During energy production, phosphate groups are 
sequentially hydrolysed from ATP, creating ADP then AMP [421]. From AMP  the 
other metabolites are generated via a number of different catabolic pathways (Figure 
4.7) [422]. It is understood that the purines are physiological regulators of leucocyte 
function and inflammation [423], but to be functional they must be released at 
appropriate loci following stimuli [424].  Inflammation in liver allografts are mainly 
associated with the DBD transplant type [425]. Previous studies on pre-transplant liver 
biopsies have shown high levels of pro-inflammatory changes [426, 427]. This may be 
responsible due to a cascade of inflammatory events that occur in the donors after brain 




inflammation but higher rates of hepatocellular damage with increasing warm ischaemia 
time [428, 429].  Since metabolites in the AMP  pathway are well known markers in 
regulating inflammation [430] and causing oxidative injury, a connection can exist 
between energy metabolism, inflammation and the extent of ischemic tissue damage 
















































Figure 4.7. Metabolic pathway of AMP, adenosine, adenine, hypoxanthine and uric acid. ATP, 
adenine triphosphate; ADP, adenine diphosphate; AMP, adenine monophosphate. 
 
AMP is converted from ATP by ectoapyrase (CD39) expressed on the cell surface [433], 
and is known to be released at the site of vascular injury when platelets aggregate; to 
promote endothelial barrier function during inflammation [422]. AMP has a role in 




[434]. Michael et al. found that gene-targeted mice with overexpression of CD39 
conferred protection in both warm and cold hepatic ischaemia [435]. This is in line with 
high levels of AMP (to serve as a protective mediator during inflammation) observed in 
DBD (Figure 4.6a). It has also been shown that dying cells as a result of ischaemia 
undergo lysis to release adenine [436]. Kartha et al. demonstrated in vitro that adenine 
nucleotides accelerated structural and functional recovery in epithelial cells [437]. This 
suggests why DBD liver allografts (Figure 4.6b) with elevated levels of adenine could 
speed up recovery time.  
To understand the potential applicability of adenine and AMP to transplantation, 
clinical outcome groups were investigated. The results found higher levels of adenine 
and AMP in IGF versus EAD (q<0.05) (Figure 4.6c). Studies have shown that adenine 
and AMP have a protective function during inflammation [434]. The elevated presence 
in IGF group also suggests that both adenine and AMP could be studied further as 
markers to predict primary graft function. In addition to being mediators for graft 
recovery, Roy et al. found that having high levels of AMP during strenuous conditions 
such as during ischaemia when oxygen is low, indicates ATP is still being generated 
[438]. One molecule of ADP phosphorylates another molecule of ADP to form ATP 
and AMP [438, 439]. During these conditions for every one molecule of ATP, six 
molecules of AMP are generated [439]. This might explain why DBD allografts and 
IGF groups show an increased level in AMP, as there may be continued energy 
metabolism improving primary graft function [440]. The prediction model in regard to 
IGF revealed that the diagnostic potential of AMP and adenine. Higher AUC and 
specificity values were observed when compared to traditional enzyme makers, which 




Furthermore, Wyatt et al. found that arresting hearts with a cardioplegic solution 
containing hypoxanthine maintained ATP content during I/R in dogs, and enhanced 
functional recovery during the post-ischemic period [441]. This explains the observed 
elevated level of hypoxanthine in DBD post-transplant stage (Figure 4.6d). In addition, 
higher amount of hypoxanthine was observed in EAD compared with IGF (q<0.05). 
Interestingly, Heshmatollah et al. in a cohort of 30 patients, observed that 29.4% of them 
who demonstrated EAD had also elevated hypoxanthine levels [442]. This suggests that 
hypoxanthine generated during ischaemia may have a link with EAD however further 
investigation is needed to support this. Although no obvious association was observed 
between hypoxanthine and  bilirubin in hyperoxia rat brain [443], correlation analysis 
performed in this study revealed negative correlation between these two molecules. 
However, the clinical evidence to support this observation is relatively weak. 
Increased level of uric acid was observed in DCD patients at pre-transplant (q< 0.001) 
(Figure 4.6e). DCD allografts are prone to IRI due to being exposed to an extensive 
period of warm ischaemia [444]. In humans, uric acid is the final product of purine 
metabolism [445]. The role of uric acid in conditions associated with oxidative stress is 
not entirely clear. However, epidemiological studies suggest that during ischaemia 
reperfusion injury, there are increased levels of uric acid which make it has potential as 
an oxidative stress marker [446]. A similar observation was made in a study conducted 
by Matthew et al., in which hepatic ischaemia was induced for 30 min followed by 60 
min of reperfusion. After ischaemia, uric acid levels had increased  by over 300% and 
during the first 30 min of reperfusion by 600% [447].  In addition, the appearance of 
EAD could act as a valid predictor of both graft failure and death in DBD allograft 




or without EAD in terms of the rate of graft failure or death [345]. In this investigation, 
a significant difference in uric acid was not observed at pre-transplant between IGF and 
EAD, and a moderate elevation was seen in EAD (q< 0.05) post transplantation (Figure 
4.6e).  Although no significant difference was seen in uric acid between DBD and DCD 
in post-transplantation, it could be related to redistribution of uric acid after reperfusion. 
Although no significant differences were seen between DBD and DCD at both 
transplantation stages (Figure 4.6b), adenosine has recently been discussed widely as a 
target for cancer immunotherapy [448]. Adenosine and ATP are generally present at 
very low levels in extracellular fluids [449]. Inflammation, ischemia, or cancer can lead 
to the release of high levels of ATP, which consequently stimulate the formation of AMP 
and adenosine [450]. In contrast to the pro-immune properties of extracellular ATP, 
extracellular adenosine can dampen the immune response through restraining effector 
cell function and stabilizing regulatory cell immunosuppression [451]. 
To understand results further, additional enzymes related with the purine pathway in 
human liver could have been measured, to understand the reasons for why particular 






In this study, the analysis of polar metabolites in the context of liver transplantation has 
identified five polar metabolites differentiated in DBD and DCD livers. Adenine and 
AMP showed higher levels in DBD group and were also elevated in recipients that 
experience IGF at pre-transplant. Other relevant molecules such as uric acid and 
hypoxanthine showed a moderate association to IRI. This study has been relevant in 
identifying pre-transplant molecules that could be related to better outcomes and tissue 
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Cholestatic liver diseases consist of primary biliary cirrhosis, familial intrahepatic 
cholestasis and intrahepatic cholestasis of pregnancy, resulting in principle and systemic 
pathology, and critically, liver failure [452]. These pathologies are characterised by the 
impairment of hepatocellular and/or cholangiocellular secretory function and bile flow, 
leading to elevation of hepatic and serum bile acid content [453]. During cholestatic 
liver diseases, aggregation of bile acids not only disrupts bile acid homeostasis directly, 
but also affects subsequent retention of lipids in the liver, ultimately preceding to 
hepatocyte injury and inflammation [454]. 
Bile is a complex biofluid produced by the liver and stored in the gallbladder. The major 
functional constituents of bile are bile acids (BAs) which are also known as steroid acids 
[455]. The release of BAs from the gallbladder to small intestine is triggered by the 
ingestion of food. As a digestive agent, BAs facilitate the absorption of lipids by 
emulsification as well as other fat-soluble vitamins through formation of micelles, which 
play an important role in regulating cholesterol homeostasis [456]. 
The production of bile acids mainly occurs in hepatocytes. There are two pathways 
responsible for the synthesis of primary BAs [457]. The classic (or neutral) pathway, 
which is the major biosynthetic pathway in human, contributes about 90% of the total 
BAs synthesis in the liver. The alternative pathway, which is also named acidic pathway 
due to the generation of acidic intermediates, produces less than 10% of the total BAs 
under routine biological conditions [458]. Two primary BAs, chenodeoxycholic acid 
(CDCA) and cholic acid (CA) are synthesized from cholesterol through the classic 




other primary bile acids, named α-muricholic acid (αMCA), β-muricholic acid 
(βMCA), and Hyocholic acid, which are transformed from CDCA. In the liver, CDCA 
and CA are conjugated with two amino acids, glycine and taurine, to synthesize 
glycochenodeoxycholic acid (GCDCA), taurochenodeoxycholic acid (TCDCA), 
glycocholic acid (GCA), and taurocholic acid (TCA). In the intestine, GCDCA, 
TCDCA, GCA and TCA yield glycodeoxycholic acid (GDCA), taurodeoxycholic acid 
(TDCA), glycolithocholic acid (GLCA) and taurolithocholic acid (TLCA) through 
bacterial dehydroxylation while CDCA undergoes epimerisation producing 
glycoursodeoxycholic acid (GUDCA) and tauroursodeoxycholic acid (TUDCA) [355]. 
When these bile acids are secreted into the lumen of the intestine, bacterial 
deconjugation and removal of the glycine and taurine groups produces the secondary 
bile acids, deoxycholic acid (DCA), lithocholic acid (LCA), hyodeoxycholic acid 
(HDCA) and ω-muricholic acid (ωMCA) [460]. These bile acids cycle through 
enterohepatic circulation where they can be taken back up into the blood stream, return 
to the liver, and be re-secreted to bile. Moreover, a fraction of CDCA is also transformed 
into tertiary bile acid, ursodeoxycholic acid (UDCA), in the liver. The illustration of 
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Figure 5.1. Bile acids synthesis in mammals. The synthesis, conjugation and deconjugation of 22 bile 
acids in mammals. Color red represents bile acids only exist in mice, not in human. 
 
Cholic acid is elevated in patients with liver disease, and rodent experimental models of 
cholestasis employing exogenous CA, e.g. via dietary supplementation, precedes 
hypercholanemia, dyslipidaemia and cholestatic symptoms [461]. Despite the increased 
knowledge of bile acid signaling and homeostasis, through identification of bile acid 
receptors, the pathogenesis of cholestasis remains unclear, with limited drug treatments 
available. While increased serum bile acids and plasma ALP and GGT remain 
diagnostic markers for cholestatic hepatic disease, there is expanding evidence for 
dysregulation of lipid homeostasis, resulting in an increase in hepatic and plasma 





In this chapter, untargeted lipidomic fingerprints and semi-targeted bile acids profile of 
liver (from 13 mice, 7 RM3 mice and 6 CA mice) and plasma (from18 mice, 8 RM3 
mice and 10 CA mice) were obtained using LC-MS approach. A work flow for this 
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Figure 5.2. Data analysis work flow for mice liver and plasma fingerprints by LC-MS. ALT, alanine 
aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transferase; ALP, alkaline 





Solvents used for LC-MS analysis including water, methanol and methyl tertiary butyl 
ether (MTBE) were LC-MS grade purchased from Sigma-Aldrich (Poole, UK). 
Ammonium formate and two internal standards, prednisolone (≥ 98% purity) and 
triglyceride (45:0) (≥ 98% purity), were purchased from Sigma-Aldrich. All other 
drugs and reagents were from Sigma-Aldrich (Dorset, U.K.) unless otherwise stated.  
 
5.2.2 Mice 
Animals were housed under temperature (22±2°C)-controlled colony rooms maintained 
under filtered positive pressure ventilation on a 12-12 h light/dark cycle beginning at 
07:00 GMT with free access to water and food. Male, 129S1/SvImJ wildtype (WT) 
littermates were used at 8-12 weeks of age. All experiments were conducted under the 
guidelines of the United Kingdom Home Office Animals (Scientific Procedures) Act 
1986 and were approved by the King’s College London Animal Care and Ethics 
Committees. All experiments were conducted in a blinded manner. Animals were 
randomly assigned to control or treatment groups. 
 
5.2.3 Dietary induction of cholestasis  
Mice were randomly allocated to receive standard animal maintenance diet (RM3, 
Special Diet Services, UK) or supplemented with 0.5% CA (0.5% CA in RM3 diet, 




weight were recorded every other day for the duration of the experiment. For 18 mice 
in total, 8 were classified for CA diet, and 10 were allocated for RM3 diet for control 
purpose. 
 
5.2.4 Plasma/liver biochemistry  
Mice were anaesthetised with isoflurane (2-3% carried in 2-3% O2) and blood samples 
were obtained via a cardiac puncture, using a heparinised syringe and needle (100 U/ml). 
Plasma was separated with centrifugation (400×g, 20 min), snap frozen in liquid nitrogen 
and stored at –80°C until processing. Whole liver was weighed and snap frozen in liquid 
nitrogen for further analysis. Plasma albumin, alanine transaminase (ALT), alkaline 
phosphate (ALP), aspartate aminotransferase (AST) and gamma-glutamyltransferase 
(GGT) levels were measured according to manufacturer’s instructions.  
 
5.2.5 Bile acids and lipids extraction 
To extract bile acids from the liver tissue, between 50 and 80 mg of tissue were obtained 
and transferred to a pre-weighed 2ml Eppendorf tube containing a steel bead (5mm, 
Qiagen, MD, US). Then, 20 µL (per 1 mg of tissue) of methanol (containing the 
negative-mode internal standard prednisolone, 10µg/mL) was added, and samples were 
homogenized for 3 min at 25 Hz (6 cycles of 0.5 min) in a TissueLyser (Qiagen, MD, 
US). Following this, samples were centrifuged with 12,000×g for 20 min at 4 ºC 




transferred to continue with the solid phase extraction (SPE) steps with a C18 cartridge 
(Bond Elut C18, Agilent, UK). Quality control samples were created by pooling excess 
supernatant from each biological sample to follow the same SPE steps [462]. 
For the extraction of the bile acids from plasma, 150 µL of methanol (containing the 
negative-mode internal standard prednisolone, 10µg/mL) was added to 50 µL of plasma, 
and vortex for 30 s. Samples were then incubated at -20 ºC for 20 min, and centrifuged 
with 12,000×g for 10 min. The supernatant was transferred to a clean vial and dried with 
nitrogen evaporator (REACTI-THERM III, Thermo Scientific, US) at 37 ºC. The 
dried residual was then reconstituted in 50 µL of methanol [355, 463]. Quality control 
samples were taken from the pool of all biological sample (10 µL from each). 
Lipidomics analysis for liver tissue was performed as described in Chapter 2.2.5. To 
extract lipids from the plasma, samples were thaw on ice and vortexed for 1 min. 20 µL 
of plasma was then mixed with 10 µL of water, 40 µL of methanol and vortexed for 2 
min (VX-2500 Multi-Tube Vortexer, VWR, US). Following this, 200 µL of MTBE 
containing 10µg/mL of internal standard (triglyceride (45:0)) was added, and vortexed 
at room temperature for 1 hour. After cooling, 50 µL of water was added, and samples 
were centrifuged at 4,000×g for 10 minutes. 50 µL of the upper MTBE layer was then 
transferred to a clean HPLC vial (with 300 µL insert) for each sample while 10 µL of 





5.2.6 Chromatographic and mass spectrometric conditions  
All extracted samples were stored at -80 ºC before injection. Details of chromatographic 
separation for lipids were provided previously (see Chapter 2.2.5). Separation of bile 
acids was achieved by using an Supelco Titan TM UHPLC C18 column (100mm × 
2.1mm, 1.9 μm), maintained at 40 °C. A gradient was employed consisting of 0.1% 
formic acid in water (mobile phase A) and 0.1% formic acid in acetonitrile (mobile phase 
B). The solvent was delivered at a flow rate of 0.5 mL/min. Gradient analysis start with 
60% mobile phase A and 40% mobile phase B for the first 4 min. Then increase to 100 % 
mobile phase B at 10 min, and maintained for 2 minutes with 100% mobile phase B. At 
12.1 min, the composition changed back to 60% mobile phase A and 40% mobile phase 
B and maintained till 15min. 
Analysis of the extracted samples was performed using Waters ACQUITY ultra-
performance liquid chromatography-quadrupole time of flight (UPLC-QToF) in 
positive ionisation mode for lipids and negative ionisation mode for bile acids [326]. For 
positive mode, a capillary voltage of 3.2 kV and a cone voltage of 45 V were used. The 
desolvation gas flow was 400 L/hour and the source temperature was 120°C. For 
negative mode, a capillary voltage of -2.7 kV and a cone voltage of 50 V were used. 
Desolvation gas flow and source temperature were fixed at 600 L/h and 300 ºC, 
respectively. All analyses were acquired using the lock spray to ensure accuracy and 
reproducibility, a reference solution leucine enkephalin was used as lock mass (m/z 
556.2771, 278.1141 for positive and 554.2615, 263.1035 for negative mode) at a 




Data were collected in the centroid mode over the mass range m/z 50–1000 with an 
acquisition time of 0.1 second per scan. 
 
5.2.7 Data processing and analysis 
Lipidomics data processing was carried out within ‘XCMS’ package in ‘R Studio’ 
(version 1.0.153). For the multivariate analysis, OPLS-DA models were built in 
SIMCA (version 14, MKS Umetrics AB, Sweden) to compare control and CA-fed mice. 
Feature selection was done using thresholds of Variable Importance for the Projection 
(VIP) score >1, loading score >0.05 and coefficient value >0.01, common features from 
these three platforms were chosen for further analysis. The identification (level 1) was 
performed by comparing structure and fragmentation patterns in the MS2 data with 
standards or in-house database. 
All identified bile acids and annotated lipids were measured in the LC-MS data using 
Waters MassLynx software (Waters Corporation, Milford, MA) and peak areas were 
normalized to internal standard.  
Permutation test was conducted based on the built OPLS-DA model in SIMCA. 
Correlation test between annotated lipids and plasma enzymes for both liver and plasma 
matrixes were performed in ‘R Studio’ (version 1.0.153). Mann-Whitney test followed 
by Benjamini-Hochberg correction was carried out to compare the selected lipid levels 
between cholestatic and control groups (bar plot generated from GraphPad Prism 6, 










5.3 Results  
5.3.1 Liver and plasma biochemistry outcomes 
With the purpose of evaluating liver injury caused by CA supplementation, mice liver 
weight, body weight and concentrations of liver enzymes (ALT, ALP, AST and GGT) 
were measured. 
Increased levels of plasma albumin, ALT, ALP, AST, GGT and liver weight/body 
weight ratio were observed in CA-fed mice. Mann–Whitney U test was applied to 
examine the statistical differences between two groups. Results are presented as mean ± 




















































































































Figure 5.3. Bar plots showing (a) Liver/BW ratios, the concentration of plasma (b) ALT, (c) AST, (d) 
Albumin, (e) ALP and (f) GGT differentiating between control and CA groups. p-value was derived 
from Mann-Whitney test (**p<0.01, ***p<0.001). CA, cholic acid; BW, body weight; ALT, alanine 






5.3.2 Bile acids  
After conducting a trial with pooled QC samples and 15 bile acid standards, targeted 
bile acid analysis featured the identification and semi-quantification of 8 bile acids, 
including CA, TCA, GCA, TCDCA, DCA, TDCA, GDCA, and TUDCA. Standards 
for individual compound were tested under the same LC-MS conditions as samples. 
The identification parameters for each standard can be seen in Table 5.1. Comparison 
of individual bile acid and the sum of 8 bile acid contents between control and CA 
groups in both liver and plasma revealed the accumulation of bile acids in CA fed mice 
(Figure 5.4).  
Table 5.1. Bile acids standards identification parameters. 
Bile Acids Retention Time (min) Mass to charge ratio 
CA 3.00 407.28 
TCA 0.74 514.28 
GCA 1.39 464.30 
TCDCA 1.22 498.29 
DCA 6.29 391.28 
TDCA 1.38 498.30 
GDCA 3.90 448.30 
TUDCA 0.77 498.30 
CA, cholic acid; TCA, taurocholic acid; GCA, glycocholic acid; TCDCA, taurochenodeoxycholic acid; 




























Figure 5.4. Bile acid levels in liver and plasma. Results were expressed as mean ± SD, p-value was 
derived from Mann-Whitney test (*p<0.05, **p<0.01). CA, cholic acid; TCA, taurocholic acid; GCA, 
glycocholic acid; TCDCA, taurochenodeoxycholic acid; DCA, deoxycholic acid; TDCA, 





In order to determine the changes in lipids associated with cholestasis, LC-MS based 
lipidomics profiling was employed on liver and plasma samples from RM3 and CA fed 
mice. More than 5,000 lipid features were obtained in lipidomic profiling, and the 
principal component analysis (PCA) was applied to all samples including QCs. From 




Figure 5.5. PCA score plot of (a) liver lipidomics showing the distribution of 4 QCs and 13 samples 
(R2 X=0.73, Q2=0.61), and (b) plasma lipidomics showing the distribution of 4 QCs and 18 samples 





After excluding the QCs, the processed data from the LC-MS experiment underwent 
supervised discriminant analysis by building orthogonal projections to latent structures-
discriminant analysis (OPLS-DA) models with liver and plasma samples for control and 




Figure 5.6. OPLS-DA score plot for distinguishing CA fed mice from control mice (a) liver, R2 





In the cholestasis model, multivariate analysis was conducted base on a limited number 
of mice. In order to assess the risk that the built OPLS-DA models could be overfitted, 
permutation plots (Figure 5.7) were included to compare the goodness of fit (R2 and Q2) 
of the original models (far to the right) with those of 20 models (further to the left) where 








In OPLS-DA analysis, apparent separation was observed between control and CA 
groups suggesting the metabolic change between them was due to the effect of CA 
supplementation. Through the comparison in both Figure 5.7a and Figure 5.7b, all blue 
Q2-values to the left are lower than the original points to the right, on top of that, the 
blue regression line of the Q2 points interacted with the vertical axis below zero. 
Permutation tests revealed that the built OPLS-DA models were valid and reliable. 15 
metabolic features which would discriminate control from cholestatic mice were 
annotated in liver, while the plasma model was interpreted by 13 metabolites. 
 
5.3.4 Statistical analysis 
Selected features from OPLS-DA models were annotated through online databases and 
in-house databases. The list of annotated metabolites was included in Table 5.. From 
the annotated metabolites, the correlation between the selected 15 lipids (in liver)/ 13 
lipids (in plasma) and 5 plasma enzymes (ALT, AST, GGT, Albumin, ALP) was 




Table 5.2. Annotated metabolites from OPLS-DA models in liver and plasma. 















TG (52:4) 28.91 872.77 
TG (50:1) 31.42 850.79 
PC (32:1) 15.79 732.55 
TG (52:2) 32.42 876.81 
CE (18:3) 26.81 664.61 
PC (36:3) 17.02 784.59 
PC (34:2) 16.37 758.58 
PC (36:2) 18.07 786.61 
TG (50:2) 29.77 848.77 
TG (52:3) 30.51 874.79 
PC (36:4) 16.49 782.58 
CE (18:1) 29.67 668.64 
CE (18:2) 28.06 666.62 
CE (16:1) 27.47 640.61 
CE (16:0) 28.92 642.62 
TG (50:2) 29.79 848.78 
PC (36:1) 18.94 788.62 





Figure 5.8. Correlation plot of 15 lipids in liver and 5 plasma enzymes. Blue represents positive 
correlation while red represents negative correlation. Intensity of ‘redness’ and ‘blueness’ represents 
correlation coefficient value. *p<0.05, **p<0.01, ***p<0.001. TG, triglyceride; PC, phosphatidylcholine; 
CE cholesterol ester; ALT, alanine transaminase; AST, aspartate aminotransferase; ALP, alkaline 
phosphate; GGT, gamma-glutamyl transferase. 
 
As shown in Figure 5.8, CE (18:1), CE (18:2), PC (36:3), PC (34:2), CE (16:1), CE 
(16:0) and CE (18:3) in liver were significantly positively correlated with ALT and 
AST (p<0.01). Furthermore, it is observed that CE (18:1), CE (16:0) in plasma 
positively associating with ALT and AST, while PC (36:3), PC (36:2), PC (36:1) and 





Figure 5.9. Correlation plot of 13 lipids in plasma and 5 plasma enzymes. Blue represents positive 
correlation while red represents negative correlation. Intensity of ‘redness’ and ‘blueness’ represents 
correlation coefficient value. *p<0.05, **p<0.01, ***p<0.001. CE cholesterol ester; TG, triglyceride; PC, 
phosphatidylcholine; LysoPC, lysophosphatidylcholine; ALT, alanine transaminase; AST, aspartate 
aminotransferase; ALP, alkaline phosphate; GGT, gamma-glutamyl transferase. 
 
Univariate analysis was applied for the panel of 15 lipids in liver and 13 lipids in plasma. 
It discovered 3 lipids putatively identified as cholesterol esters (CE) and 2 
phosphocholines (PC) that showed significant differences between control and CA-fed 
mice in both liver and plasma profiles (Figure 5.10). The concentrations of CE (16:0), 
CE (16:1) and CE (18:1) were significantly higher in CA-fed mice, while levels of PC 




































































































































































































































Figure 5.10. Comparison of 5 common lipid contents in liver and plasma between CA-fed and control 
mice. (a) CE (16:0), (b) CE (16:1), (c) CE (18:1), (d) PC (36:3) and (e) PC (34:2). Results represented 
as mean ± SD, p-value was derived from Mann-Whitney test followed by Benjamini-Hochberg correction 
(*p<0.05, **p<0.01, ***p<0.001). CE cholesterol ester; PC, phosphatidylcholine. 
 
The utility of the five selected lipids (3 CEs and 2 PCs) was then tested by comparing 
with total bile acids (based on 8 targeted analysed bile acids) and plasma enzymes (ALP 




from receiver operating characteristic (ROC) curve (Figure 5.11). AUC of 77.5%, 
100%, 91.2% for bile acids sum, five lipids and two enzymes were observed.   
 
Figure 5.11. ROC curve for comparison of bile acids sum, 5 lipids and plasma enzymes. Bile acids sum, 
5 lipids and plasma enzymes resulted in AUC of 77.5%, 100% and 91.2% respectively. CE cholesterol 






Here, a combination of untargeted lipidomics approach and semi- targeted bile acid 
method using LC-MS was employed to investigate the changes in liver and plasma of 
CA induced cholestatic mouse.  
The outcomes of liver and plasma biochemistry test revealed significant hepatic injury, 
featuring accelerated serum enzymes levels and enlarged liver weight/BW ratio (Figure 
5.3), caused by CA supplementation in mice [461, 464].  
Although 15 standards were tested in a separate trial, only 8 bile acids were detected. 
This is possibly related to the fact that the concentrations of some bile acids are below 
the limit of detection of the applied instrument.  By applying semi-targeted analysis for 
8 bile acids, CA, GCA, DCA, TDCA and the sum in liver showed higher content, 
specifically increased levels of plasma CA, TCA, DCA and the sum were observed in 
CA-fed mice. The impaired bile flows result in accumulation of bile acids in liver [458], 
and lead to a build-up in plasma and in the circulation. Consistently, we observed 
elevated levels of bile acids (BAs), including primary and secondary bile acids, in both 
liver and plasma samples of CA-fed mice. In addition to their detergent effects, 
accumulation of BAs promotes hepatotoxicity via several mechanisms, including 
mitochondrial damage, promotion of inflammation, and, ultimately, apoptosis and 
necrosis [2, 465].  
Through conducting multivariate lipidomics analysis, the reproducibility of the 




Figure 5.5b, QCs represented in green dots clustered together near the centre of the plot, 
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Correlation analyses were subsequently carried out to find the association between the 
chosen metabolic features and plasma enzymes. The panel of lipids, mostly PCs and CEs, 
derived from the multivariate analysis presented to correlate with hepatic injury markers 
(Figure 5.8 and Figure 5.9). Furthermore, the followed univariate analysis of selected 
common lipids in liver revealed the accelerated contents of three cholesterol esters and 
two phosphatidylcholines in cholestatic mice (Figure 5.10).  
Cholesterol esters are derived from cholesterol, which is mainly synthesized in the liver. 
They then can be transported to the plasma by lipoproteins [466]. A study revealed that 
CE (18:1), CE (16:0) and CE (16:1) account for about 24%, 12% and 3% of the total 
fatty acids measured in human plasma cholesterol esters respectively [467]. On top of 
that, the structure and functionality of all membrane systems are maintained by 
phospholipid bilayers. Furthermore, phosphatidylcholine is the most abundant 
phospholipid of eukaryotic membranes [468]. PC (34:2) was found to be up regulated 
in tissue and serum of various diseases, including lung, colorectal, gastric and thyroid 
papillary cancer, while increased expression of PC (36:3) was observed to be related 
with alcohol liver injury [469-471].  
The excretion of PC is critical, accumulated PC could facilitate the bile toxicity by 
attenuating the formation of mixed micelles with BAs and cholesterol [8, 472]. It has 
also been found in other studies that the cholesterol ester transfer activity was reduced 




gathering of CE [474]. Although the same trend of CEs alteration was observed in 
plasma, PC levels decreased in the disease group. In healthy controls, most of the 
circulating CE are formed in plasma through the cholesterol acyltransferase (LCAT) 
reaction, where LCAT transfers fatty acids from PC to cholesterol through high density 
lipoprotein (HDL)[474]. With the higher concentration of both HDL and LCAT 
detected in plasma of human and rodent with hepatic disease [473, 475], plasma PC 
levels declined in cholestatic mice as seen in this study (Figure 5.12).  
With the aim of broaden the pool of reliable markers for cholestasis diagnosis, the 
prediction ability of the selected five lipids, total bile acids examined in this study and 
the combination of two plasma enzymes ALP, GGT were compared using ROC curve 
(Figure 5.11). The AUC for these three different classes of markers demonstrated that 
the chosen five lipids could be employed, if reproduced in humans, as a novel tool for 















Cholesterol + PC                 Cholesterol ester    + LysoPC LCAT
 
Figure 5.12. Graphic illustration of cholesterol, cholesterol ester and phosphatidylcholine 
transportation between liver and plasma. ACAT, acyl-CoA cholesterol acyl transferase; HDL, high-








In this preliminary study, the main finding to emerge is that a combination of five lipids 
including three phosphatidylcholines and two cholesterol esters showed significant 
differences in terms of concentrations between cholestatic mice and the controls. Also, 
the panel of lipids correlated well with plasma enzymes. By comparing the plasma lipid 
metabolites with traditional cholestatic indicators of enzymes and bile acids, better 
prediction ability was observed. Hence, this panel of lipids have good potential to 
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Sepsis, induced by infection, can cause physiologic, pathologic, and biochemical 
abnormalities [476]. Recently, the new definition of sepsis has been refined as ‘life-
threatening organ dysfunction caused by a dysregulated host response to infection’ 
[155]. There has been a rapid increase of sepsis cases worldwide, claiming 
approximately 6 million lives every year [477]. Although enormous improvements in 
modern medicine have been achieved, only minor progress has been reached in the 
realm of sepsis as a consequence of insufficient preventive vaccines and therapeutic 
measures [478].  
Despite efforts made for the prompt identification and supportive care of sepsis, 
including early antibiotics, fluid resuscitation and source control, mortality due to sepsis 
still ranks second after deaths from heart attack [477, 479]. Surprisingly, recent studies 
commissioned by the UK Sepsis Trust showed that sepsis affects 260,000 people every 
year, while long term complications due to delayed diagnosis were found to be costing 
the UK economy as much as £15.6 billion annually. The fatalities of sepsis in England 
and Wales increases from 2,136 in 2013 to 2,833 in 2016 [480]. 
The screening of sepsis can be accomplished by evaluating clinical variables, including 
Glasgow coma scale score, systolic blood pressure, respiratory rate, serum creatinine and 
bilirubin, using the criteria of both quick Sequential Organ Failure Assessment (qSOFA) 
and SOFA which are bedside prompts that may identify patients with suspected 
infection who are at greater risk for a poor outcome outside the intensive care unit  [155]. 




vasopressors to maintain mean arterial pressure (MAP) ≥65 mm Hg due to hypotension 
and with serum lactate levels >2 mmol/L [481].  
Since the human body’s response to critical blood infection can be identical to its 
response to other non-infectious triggers [482], it is not easy for clinicians to tell how 
severe the infection is until organs fail, thus, the discovery of new biomarkers as a tool 
for aiding early diagnosis and rapid appropriate therapies for patients with sepsis can 
improve patient outcomes greatly [198]. In 2010, 178 sepsis biomarkers were evaluated 
in 3370 studies as reported by Pierrakos et al. in their review of the literature [199]. 
From those, biomarkers such as procalcitonin, presepsin, C-creative protein (CPR), 
CD64, soluble-urokinase-type-plasminogen-activator-receptor (suPAR), soluble 
triggering receptor expressed on myeloid cells 1 (sTREM-1), IL-6, IL-27, cell-free 
plasma DNA (cfDNA) and miRNAs have attracted extensive interests [200-202].  
Studies applying genomics and proteomics provided a rationale for researchers to 
consider assessing broader combinations of biomarkers that may improve the real-time 
diagnostic and prognostic capabilities [198, 483-485]. To learn more about biomarkers 
in sepsis, a murine model of sepsis has been investigated by utilising metabolomics in 









Solvents used for LC-MS analysis including water, methanol and methyl tertiary butyl 
ether (MTBE) were LC-MS grade purchased from Sigma-Aldrich (Poole, UK). 
Ammonium formate and internal standards triglyceride (45:0) (≥ 98% purity), were 
purchased from Sigma-Aldrich. All other drugs and reagents were from Sigma-Aldrich 
(Dorset, U.K.) unless otherwise stated.  
 
6.2.2 Mice 
Animals were housed under temperature (22±2°C)-controlled colony rooms maintained 
under filtered positive pressure ventilation on a 12-12 h light/dark cycle beginning at 
07:00 GMT with free access to water and food. Male, 129S1/SvImJ wildtype (WT) 
littermates were used at 8-12 weeks of age. All experiments were conducted under the 
guidelines of the United Kingdom Home Office Animals (Scientific Procedures) Act 
1986 and were approved by the King’s College London Animal Care and Ethics 
Committees. All experiments were conducted in a blinded manner. Animals were 
randomly assigned to control or treatment groups. 
 
6.2.3 Plasma/liver/brain biochemistry 
Mice received a single intraperitoneal (i.p.) injection of phosphate buffered saline (PBS) 




coli Serotype 111: B4) or vehicle (PBS, 10 ml/kg). For 10 mice in total, 6 received LPS 
and were classified as septic mice, and 4 were allocated as control mice (vehicle-treated). 
After 18h, mice were anaesthetised with isoflurane (2-3% carried in 2-3% O2). Blood 
samples were obtained via a cardiac puncture, using a heparinised syringe and needle 
(100 U/ml), in the meanwhile, a laparotomy was performed for collection of the 
peritoneal lavage fluid (PELF). For this, the peritoneal cavity was washed with 3 ml of 
PBS. Plasma was separated by centrifugation (400×g, 20 min), snap frozen in liquid 
nitrogen and stored at –80°C with PELF until processing. Due to the sample volume 
limitation, plasma was stored for examining biochemistry parameters, and only whole 
liver and brain were weighed and snap frozen in liquid nitrogen for further metabolomics 
analysis. Body weight, blood pressure and temperature recordings were taken prior 
(baseline) and 18h post-LPS. Plasma aspartate aminotransferase (AST), glucose and 
peritoneal cytokine levels (interleukin (IL) -6, IL-10, tumour necrosis factor-alpha 
(TNF-α), keratinocyte-derived chemokine (KC) were measured according to 
manufacturer’s instruction Severity scores of sepsis were also evaluated for each mouse 
[486]. 
 
6.2.4 Metabolomics analysis 
Sample treatment procedures for mouse liver and brain were conducted as depicted in 
Chapter 2.2.5. For the extracted samples, ether phase was analysed under the same 
conditions stated in Chapter 2.2.5, while the investigation of aqueous phase was 
conducted following details previously provided (see Chapter 4.2.3). All extracted 




phase analyses were consistent as described in Chapter 2.2.5, while the same conditions 
were applied for aqueous phase analyses as listed in Chapter 4.2.3. 
6.2.5 Data processing and analysis 
Data pre-processing was performed within ‘XCMS’ package in ‘R Studio’ (version 
1.0.153) and exported into SIMCA version 13 (MKS Umetrics AB, Sweden) for 
multivariate analysis. Data matrix of RP (+), RP (-), HILIC (+) and HILIC (-) modes 
from liver and brain samples were processed with normalisation, transformation steps 
respectively, features with relative standard deviation (RSD) < 30% in QC samples 
were chosen from each dataset. The combination of selected features from the same 
phase of the extracted samples (liver RP, liver HILIC, brain RP, brain HILIC) were 
used for the following model analysis. All model analyses were conducted in R-Studio 
1.0.153 (Boston, MA, USA). 
Random forest (RF) analysis (500 trees), was conducted to identify metabolites that 
could distinguish septic and control mice using ‘randomForest’ package. Contributions 
of individual predictors were measured by ‘variable importance’ score. Variable 
importance scores greater (less) than 0 suggests an increase (decrease) in prediction 
accuracy. The top 20 variables in variable importance score (> 0) list in descending order 
were selected in individual models. 
Elastic net regression, a type of regularised, or penalized logistic regression (RLR) 
analysis was applied for binary outcome (sepsis or control) using ‘glmnet’ package. 
Significant variables (non-zero coefficients) were shown based on p-values in output 




Orthogonal Partial Least Square Discriminant Analysis (OPLS-DA) models were built 
in SIMCA 14 (Umetrics, Sweden) to compare control and septic mice. Feature 
selection was done through investigating variable importance projection (VIP) scores 
and s-plots, the common features from these two platforms (top 50) were chosen. 
As mentioned above, three statistical models including random forest, regularised 
logistic regression and OPLS-DA were built for comparison of sepsis and control groups. 
Overlapping features from any two models were chosen and combined for four 
analytical modes. Power analysis, FDR (false discovery rate) control and correlation 
with biological data were conducted for liver and brain variables separately. Details of 





Liver data Brain data








Select overlapping features 
from any two statistical models
Power analysis and FDR control
Sepsis vs. Control
Correlation with cytokines
RP (+), RP (-), HILIC (+), HILIC (-)
liver RP , liver HILIC, brain RP, brain HILIC
 
Figure 6.1. Data analysis workflow for mouse liver and brain in a septic model. RP, reverse phase; 
HILIC, hydrophilic interaction chromatography; OPLS-DA, orthogonal projections to latent structures-
discriminant analysis; VIP, variable importance projection; FDR, false discovery rate. 
 
The annotation (level 2 confidence) was performed by comparing fragmentation 
patterns in the MS2 data and retention times with in-house and online database 
(HMDB). All annotated features were measured in the LC-MS data using Waters 
MassLynx software (Waters Corporation, Milford, MA). Peak areas were normalized 




6.3 Results and Discussion 
6.3.1 Systemic and biochemistry outcomes 
Details of systemic and biochemistry parameters are listed in Table 6.1. Fever/low 
temperature and hypotension are common characteristics of sepsis, and cytokine tests 
have been widely applied for further diagnosis. Changes in body temperature, blood 
pressure and body weight after LPS injection can be seen in the septic group. Significant 
differences were observed between sepsis and control groups for all other outcomes 
except AST levels. Pro-inflammatory cytokines IL-6, and TNF-α; and anti-
inflammatory cytokine IL-10 were employed as biomarkers in the context of sepsis 
severity for evaluation purpose, and they have been demonstrated with high prediction 
ability [487, 488]. KC, a chemoattractant for neutrophils, up-regulated in septic mice as 
it plays a critical role in the course of systemic inflammation [489]. From the comparison 
above, it shows that mice were septic after LPS induction. 
Table 6.1. Systemic and biochemistry outcomes in control and sepsis groups.  
Outcomes Control Sepsis 
Severity score 4.00 (0) 8.50 (0.55) * 
Drop in body temperature (%) -0.28 (1.22) 9.64 (7.32) * 
Drop in blood pressure (%) -16.18 (4.84) 54.94 (11.03) * 
Drop in body weight (%) 2.56 (3.98) 12.84 (11.19) * 
Glucose levels (mmol/l) 12.42 (2.31) 3.82 (1.73) * 
Plasma AST levels (milliunits/ml) 122.10 (32.25) 138.34 (46.12) 
PELF IL-10 levels (pg/ml) 254.45 (6.63) 309.66 (29.70) * 
PELF TNF-α levels (pg/ml) 46.95 (5.34) 68.58 (14.03) * 
PELF IL-6 levels (pg/ml) 1338.70 (137.98) 9822.33 (4822.91) * 
PELF KC levels (pg/ml) 253.53 (153.66) 3707.86 (1644.94) * 
AST, aspartate aminotransferase; PELF, peritoneal lavage fluid; IL, interleukin; KC, keratinocyte-





Although these are standard markers of sepsis, they can also be used as markers for other 
inflammatory disease, such as diabetes, atherosclerosis and Parkinson’s disease [490-
492]. 
 
6.3.2 Data pre-processing 
More than 20,000 features were detected using UPLC-Q-ToF under the stated 
chromatographic and mass spectrometric conditions. Raw data files were processed 
with ‘xcms’ package in R, quantile normalisation and log transformation were applied 
to the four data matrixes. 
QC samples were investigated to select features with RSD less than 30%. For liver RP 
positive data, 2383 out of 4861 features were picked, while 568 out of 664 features met 
the criteria in negative data. For liver data derived from HILIC positive mode, 1840 out 
of 2862 features were chosen, while 1161 out of 2944 features from the HILIC negative 
mode met the standard. Comparatively, for brain RP positive profiles, 2989 out of 3941 
features had RSD less than 30%, and 955 out of 1120 fingerprints were selected from 
brain RP negative data. For brain data obtained in HILIC positive mode, 1886 out of 
2615 features were picked, and 1655 out of 2492 features passed the requirement of 
RSD<30% in negative mode.  
With the application of pre-processing steps, the resulting Principal Component 
Analysis (PCA) score plots showed that QC samples clustered near the origin suggesting 
features were robustly detected and reproduced during the analysis. Plots for each 




Table 6.2. Feature selection with RSD value in QC samples. 
Dataset Total RSD < 30% in QC samples 
Liver RP (+) 4861 2383 
Liver RP (-) 664 568 
Liver HILIC (+) 2862 1840 
Liver HILIC (-) 2944 1161 
Brain RP (+) 3941 2989 
Brain RP (-) 1120 955 
Brain HILIC (+) 2615 1886 
Brain HILIC (-) 2492 1655 













Figure 6.2. PCA plots of liver and brain data with different chromatographic and mass spectrometric 





6.3.3 Model analysis 
The Random forest (RF) approach was used to identify the top 20 lipids, in terms of 
their importance score in each dataset after pre-processing. RF is a versatile classification 
algorithm which can capture complex and non-linear relationship between predictors 
and outcomes [493]. It differs from PCA (a dimensionality reduction algorithm), which 
identifies the hyper-plane closest to the data and projects the data onto it, instead the 
RF method relies on the assembling of decision trees built with random selection of 
features. This machine learning method provides two aspects that are very informative 
for data mining: high prediction accuracy and information on variable importance for 
classification [494].  
By applying the elastic net regression (regularised logistic regression), variables with 
non-zero coefficients were extracted from the output. Elastic net regression is a hybrid 
approach that blends both penalization of the lasso and ridge regression while separating 
the two groups with minimizing mean-squared error (MSE). As an approach for 
prediction modelling, it is suitable for both large data sets (bioinformatics, neuroimaging) 
and data sets with high dimensionality and small sample size like the dataset in this 
project [495, 496]. From the statistical perspective, elastic net regression controls  for 
the effects of the overfitting and multicollinearity [497]. 
OPLS-DA models were built for all four combined datasets. For liver RP data 
(R2X=0.624, Q2=0.96), CV-ANOVA p value (1.08×10-2) suggested the model to be 
reliable, and the R2Y= 0.995 in score plot indicated a good discrimination between 
septic and control mice. Similarly, CV-ANOVA p value of 2.43×10-4 and the R2Y value 




Q2=0.978). For brain RP data (R2X=0.742, Q2=0.577), the CV-ANOVA p value of 
2.84×10-2 and the R2Y value of 0.955 demonstrated segregation between groups. CV-
ANOVA p value (2.23×10-2) in brain HILIC data (R2X=0.458, Q2=0.623) explained 
the model to be valid, and the R2Y= 0.969 in score plot revealed a good discrimination. 
Overlapping features from any two of the above-mentioned data treatment models were 
selected. As shown in Figure 6.3, there were 31 features chosen in liver data, including 
13 from RP, and 18 from HILIC mode. Similarly, a total of 23 features were selected in 










6.3.4 Univariate analysis 
From all 54 selected features shown in the Venn diagram, 20 metabolites were annotated. 
The annotations of the metabolites can be found in Table 6.3. Due to the limitation of 
the small sample size in this study, post hoc power analysis (alpha=0.05, power=0.8) was 
applied to examine the sample size needed for each annotated metabolite. From 20 
annotated metabolites, 9 passed the power analysis threshold, where the differences 
between septic and control groups can be detected with the quantity of samples 
employed in this study. Additionally, Benjamini- Hochberg correction was conducted 
for FDR control following the Mann- Whitney test between control and sepsis groups 
on 9 metabolites. Plots of these metabolites including 3 cholesterol esters (CE), 2 
phosphatidylethanolamines (PE), lysophosphocholines (LysoPC) (16:0), pyruvate, 
fumarate and glycerylphosphorylethanolamine (GPE) can be seen in Figure 6.4. Results 
were presented as mean ± SD, QC samples were also included in the bar plots to easily 
compare the analytical variation of chosen metabolites. 
Significant differences were observed in the levels of CE (18:1), CE (16:0), CE (18:2), 
LysoPC (16:0), pyruvate, fumarate and GPE in liver between control and sepsis groups. 
Comparatively, the content of CE (18:2), PE (p38:0) and GPE showed differences in 
the brain profile. Among these 9 metabolites, pyruvate and fumarate showed opposite 
trends in liver and brain regarding their concentrations when comparing sepsis and 
control samples.  
Both CE (18:1), CE (16:0) exhibited increased levels in the liver and plasma of 
cholestatic mice as studied in Chapter 5, whereas studies have shown that sepsis 




accumulation induced by hypercholesterolaemia promotes inflammatory responses in 
conditions like sepsis [500]. However, the stimulated inflammatory response could also 
lead to decreased cholesterol efflux [501], which results in reduction of cholesterol esters, 
a downstream product of cholesterol, as shown in  Figure 6.4.  
Table 6.3. Annotated metabolites from the common features in three statistical models. 
CE, cholesterol ester; SM, sphingomyelin; LysoPC, lysophosphocholines; AMP, adenosine 
monophosphate; PE, phosphatidylethanolamine; PC, phosphocholine; PI, phosphatidylinositol; RP, 
reverse phase positive; HN, HILIC negative; RN, reverse phase negative. 
 
 
 Metabolites Retention 
time (min) 







CE (18:1) 29.57 668.64 RP 
SM (40:2) 23.97 786.66 RP 
CE (16:0) 28.84 642.62 RP 
CE (18:2) 27.96 666.62 RP 
LysoPC (16:0) 3.34 496.34 RP 








PE (40:5) 16.96 792.57 RN 
PE (p38:0) 19.76 818.64 RN 
PE (33:1) 16.35 762.53 RN 
PC (35:4) 18.13 766.55 RN 
PE (38:4) 16.45 766.55 RN 
PE (p36:2) 17.71 772.54 RN 
PE (42:4) 17.41 804.59 RN 
PI (38:4) 16.02 885.57 RN 
PE (46:4) 19.55 860.65 RN 
PE (p40:0) 20.02 846.67 RN 
Pyruvate 11.45 87.01 HN 
Fumarate 11.46 115.00 HN 
GPE 16.76 214.05 HN 















































































































Figure 6.4. Bar plots of 9 metabolite profiles in liver and brain samples. Normalised peak area was 
illustrated as mean ± SD, p-values were derived from Mann-Whitney test followed by Benjamini-
Hochberg correction (*p<0.05, **p<0.01, ***p<0.001). 
 
Interestingly, LysoPC (16:0) has been investigated in Chapter 2, and higher amount in 
the liver tissue of donation after circulatory death (DCD) patients was observed when 




inflammatory changes were also discovered [54]. Additionally, it presented elevated 
level in the group of patients who showed early allograft disfunction (EAD) after liver 
transplantation. Furthermore, decreased plasma concentration of various LysoPC 
species including LysoPC (16:0) was observed in a study involving 102 sepsis patient 
and 56 healthy controls [502], which is consistent with the findings in this chapter. 
Fumarate concentration significantly diminished in the liver of sepsis mice (Figure 6.4). 
This could be associated with a biochemical mechanism within the mitochondria where 
the oxidation of succinate to fumarate is inverted in sepsis, leading to fumarate reduction 
[503]. In addition, the TCA cycle where fumarate participates might have been 
hampered by LPS injection in our sepsis model, which can trigger the blockade of the 
TCA cycle [504]. Similarly, the apparent decline of pyruvate suggests an inhibition of 
glycolysis where pyruvate is the end product [504]. Although their levels elevated in 
brain profiles, it could be linked with an enhanced energy metabolism in brain with 
septic conditions [505, 506]. Heath et al. found that hyperdynamic state was observed 
in sepsis patients for weeks or even months, where the energy demand was increased 
[507]. In addition, it was observed that sepsis did not hinder the ability of brain to 
maintain high energy metabolism during hypoxia in rats [508].  
Phosphatidylethanolamine, one of the most studied phospholipids in the context of cell 
death, can flip from the inner plasma membrane to the outer membrane during 
inflammation inducing cell death dynamics [509, 510]. With the accumulation of PE 
after cell death, significantly elevated amounts of PE were observed in septic mice brain 
tissue. As the intermediate in the catabolism of PE [511], GPE (Figure 6.5) 




demonstrated to be essential for anticoagulation activity, and its altered levels could be 
associated with coagulation and vascular endothelial dysfunction during severe sepsis 
[512, 513].  
 
 
Figure 6.5. Pathway of glycerylphosphorylethanolamine (GPE) from PE. 
 
6.3.5 Correlation analysis 
Spearman correlation analyses between the 9 annotated metabolites, 4 PELF cytokines 
and systemic response factors (glucose level, drop in body temperature, blood pressure 




esters were highly positively correlated with each other (all r > 0.9 and p < 0.001) in the 
liver profile. Strong correlation was also observed between Pyruvate and fumarate, as 
well as between IL-6 and TNF-α, KC (all r > 0.9 and p < 0.001). Moderate correlations 
were observed between LysoPC (16:0), pyruvate, fumarate and three CE molecules (all 
r > 0.7 and p < 0.01). Additionally, negative correlations were discovered between 
LysoPC (16:0), pyruvate, fumarate, GPE and the four investigated cytokines (all r < -
0.65 and p < 0.05) while pyruvate, fumarate and GPE correlated positively with glucose 
level (all r > 0.75 and p < 0.01). 
 
Figure 6.6. Correlation plot of 9 metabolites in liver, 4 PELF cytokines and systemic response factors. 
Correlation coefficients were listed at the lower part of the plot, blue represents positive correlation while 
red represents negative correlation. Intensity of ‘redness’ and ‘blueness’ represents correlation coefficient 




Correlation analyses for 9 metabolites in the brain profile, 4 PELF cytokines and 
systemic response factors (glucose level, drop in body temperature, blood pressure and 
body weight) were illustrated in Figure 6.7. Similar correlation matrix can be seen for 
brain data when compared with liver data. Very strong positive correlation can be seen 
between Pyruvate and fumarate, GPE and glucose, as well as between IL-6 and TNF-
α, KC (all r > 0.9 and p < 0.001). Contrastingly, PE (p40:0) correlated negatively and 
significantly with CE (16:0) and CE (18:2) (all r > 0.9 and p < 0.001). Moderate 
correlation between GPE and all four cytokines was observed (all r < -0.7 and p < 0.05). 
 
Figure 6.7. Correlation plot of 9 metabolites in brain, 4 PELF cytokines and systemic response factors. 
Correlation coefficients were listed at the lower part of the plot, blue represents positive correlation while 
red represents negative correlation. Intensity of ‘redness’ and ‘blueness’ represents correlation coefficient 




Among the panel of 9 metabolites, GPE in liver and brain both showed correlation with 
inflammatory cytokines (-), glucose level (+) and drop in body temperature (-). GPE is 
involved in maintaining membrane fluidity, and being the essential source of the key 
components of the phospholipid bilayer, PE and phosphatidylcholine (PC) [514]. It is 
known to improve the cognitive impairment that occurs in many neurodegenerative 





In summary, metabolomics approach was applied here to explore potential metabolite 
indicators for sepsis utilising both mouse liver and brain tissue. With the combination of 
three multivariate analytical tools including random forest, regularised logistic 
regression and OPLS-DA, a panel of 9 annotated metabolites was established. Through 
the correlation analyses, glycerylphosphorylethanolamine was selected as a putative 
biomarker which was depleted in septic mice and very highly correlated with 










7.1 Final conclusions 
Liver related diseases are rapidly becoming a major global burden. Metabolomics can 
provide a window to view the biochemistry occurring in the transitional phases between 
a healthy liver and a diseased liver. Whether provoked by diabetes, cholestasis, alcohol 
use, sepsis or oncogenic viruses, the liver develops a core metabolomic phenotype that 
involves dysregulation of bile acid and lipid homeostasis. Considering these key changes 
in metabolism, a metabolomic approach can shed light on the overall biochemistry in 
the liver and help designing diagnostic and/or progression tests associated with hepato-
related diseases. To this end several studies were designed and undertaken in this 
program of research, and the results were presented and discussed in this thesis. Putative 
markers identified in each chapter were listed in Error! Reference source not found.. 
Table 7.1. List of putative markers identified in each chapter. 
Liver Diseases IRI Allograft 
Function  






   
Chapter 3  
Liver Transplantation 




























IRI, Ischaemia reperfusion injury; LysoPC, Lysophosphatidylcholine; Cer, Ceramide; AMP, adenine 
monophosphate; CE, cholesterol ester; PC, phosphatidylcholine; PE, phosphatidylethanolamine; GPE, 
glycerylphosphorylethanolamine. 
 
In chapter 2, reversed phase-mass spectrometry (RP-MS) was employed to compare 
lipid fingerprints between 76 DBD (donation after brain death) and 36 DCD (donation 
after circulatory death) matched pre- and post-transplant liver biopsies. The results 
suggested that two LysoPCs could play a role in perpetrating tissue damage induced by 
warm ischaemia. This can be further supported by the fact that higher levels of these 
two LysoPCs were observed in recipients undergoing early allograft dysfunction (EAD) 
(p < 0.05) when compared with immediate graft function (IGF) group. Additionally, 
they were also found to correlate with AST concentration at post-transplant. Studies 
suggest that free fatty acids mediated cytotoxicity in liver diseases, such as NAFLD, is 
indirect via the generation of the toxic metabolite, LysoPC. Rationally designed 
therapies can hopefully be developed if LPC-mediated pathways for lipotoxicity can 
been elucidated [517], Lehmann et al. also found that LysoPCs are able to separate the 
insulin-sensitive from the insulin-resistant NAFLD group in humans and may highlight 
important pathways in the pathogenesis of fatty liver induced insulin resistance [518]. 
In chapter 3, we were interested in measuring lipids that are known to induce 
inflammation since ischaemia reperfusion injury (IRI) is associated with the release of 




carried out in 20 DBD and 26 DCD paired liver samples. Increased levels of C18 and 
C20 ceramides and diminished levels of C24 ceramide were observed in DBD post-
transplant phase compared with pre-transplant phase (p<0.05), C22 ceramide showed 
more pronounced changes in the DCD group. C18 ceramide was found to be associated 
with post-transplant international ratio (INR) creatinine and bilirubin, three common 
markers of liver dysfunction. The work in this chapter therefore contributed to the 
growing body of evidence highlighting the involvement of C18 ceramide in IRI in DCD. 
Other researchers have revealed that a decrease in C24 ceramide serum levels was 
associated with severity of liver fibrosis in HCV patients, and was proposed as a 
promising novel biomarker in chronic HCV infection [519]. It was also reported that 
increased hepatic long-chain ceramides were associated with apoptosis (C16 and C18) 
and that decreased very-long-chain ceramide C24 are involved in insulin signalling 
[520]. 
In chapter 4, hydrophilic interaction chromatography-MS (HILIC-MS) analysis was 
performed on 35 DBD and 12 DCD paired liver samples (n=94). Sample subset was 
divided into training set (30 DBD, 5 DCD) and test set (5 DBD, 7 DCD). Subsequent 
orthogonal projections to latent structures-discriminant analysis (OPLS-DA) modelling 
highlighted five purine metabolites, including adenine, adenosine, adenosine 
monophosphate (AMP), hypoxanthine and uric acid. Elevated levels of AMP and 
adenine were found in the DBD vs.  DCD models at both transplant stages (p<0.01), 
after conducting univariate analysis. These changes were also seen in pre-transplant 
biopsies from recipients experiencing immediate graft function (IGF) (p<0.05). In the 
meanwhile, the prognostic value in terms of receiver operating characteristic (ROC) 




values of traditional enzyme markers. The findings suggested that they may associate to 
healthy allograft function and a test could improve graft survival rate. Interestingly, it 
was reported that the activation of AMP-activated protein kinase in liver decreased 
lipogenesis and protected against hepatic steatosis when mice were fed a high-fructose 
diet. It is also protective against hepatic triglyceride accumulation, which leads to 
NAFLD [521].   
In chapter 5, now in animal models, untargeted lipidomic analysis and semi-targeted 
analysis of 8 bile acids were performed on 6 cholestatic and 7 control mouse liver 
samples, as well as on 10 cholestatic and 8 control mouse plasma samples in search of 
cholestasis biomarkers. A combination of 15 liver lipid features and 13 plasma lipid 
features consisting of cholesteryl ester (CE), triglycerides (TG) and 
phosphatidylcholines (PC) was identified and the correlation analyses among this panel 
and 5 plasma enzymes were conducted. In addition, common features from liver and 
plasma matrixes demonstrated close correlations with enzymes were selected for further 
univariate analysis. Two PCs and three CEs showed significant differences between 
cholestatic and control mice (p<0.05). Further, ROC curve revealed a high potential of 
these five lipids in discriminating cholestatic mice from controls, with AUC of 100%, 
when compared to plasma enzymes (91.2%) and bile acids (77.5%). Cholesterol and 
PC can form CE and LysoPC with the assistance of lipoproteins, the changes of these 
lipids can be used as biomarkers of the degree of cholestasis, with serum cholesterol 
being an even more sensitive marker of cholestasis among early-stage PBC patients than 




In the last chapter, the interest shifted toward sepsis in order to understand inflammation 
in the liver and the connection between liver-brain axis. Liquid Chromatography-Mass 
Spectrometry (LC-MS) was applied on liver and brain biopsies from 6 septic and 4 
control mice. To maximize detection of metabolite numbers, two orthogonal LC 
methods, PR and HILIC, were employed. This experimental design allowed detection 
of more than 20,000 metabolic features. A panel of 9 annotated metabolites, including 
previously discussed LysoPC (16:0), CE (16:0) and CE (18:1), were uncovered through 
a meta-analysis which employed three machine learning tools. Mann -Whitney tests 
and spearman correlation analyses revealed glycerylphosphorylethanolamine (GPE) 
depleting in both liver and brain from septic mice (p<0.05) and correlating strongly with 
conventional sepsis markers. It implicated that GPE can act as a candidate biomarker 
for endothelial dysfunction during sepsis. 
In summary, chapter 2, 3 and 4 supported the general hypothesis in liver transplantation, 
addressing the practical possibilities of novel biomarkers being tested in the clinic. In 
chapter 5 and 6, the metabolomics strategy was applied to two mouse models of liver 
related diseases. Overall, this thesis has shown that, metabolic profiling techniques of 
various biological samples have a practical application in the discovery of metabolic 
signatures associated with a number of liver related diseases. Nowadays, personal 
medicine has been a new dimension in patient care with the power of disease diagnosis, 
prognosis and therapeutic response monitoring. Metabolomics which provides a global 
view of health with integrated output of multiple systems and organs can be a valuable 





7.2 Future directions 
7.2.1 Further validation of markers 
In Chapter 2, 3 and 4, we were able to identify a few liver tissue metabolic features 
associated with organ damage, inflammation or function. However, liver biopsies are 
not easily accessible in clinic. Additional validations of these markers with donor blood 
samples would facilitate the evaluation process. Furthermore, since both normothermic 
machine perfusion and living donation (LD) have been demonstrated to show reduced 
level of graft injury, measurements of these markers from normothermic perfused and 
LD biopsies are of great interest. 
In chapter 5 and 6, animal models of cholestasis and sepsis, respectively, consisted of 
small sized sample cohorts. Therefore, another interest for the future work involving 
animal samples would be to validate metabolites in a separate larger-scale sample set.  
It is plausible to work towards conducting a clinical trial of two LysoPC biomarkers 
which were found to be associated with liver damage, and to ascertain how to 
supplement the transplanted livers with AMP and adenine which were are depleted, in 





7.2.2 Metabolite identification 
One of the major challenges in metabolomics studies is the identification of metabolites. 
Compared to peptides consisting of amino acids repeatedly arranged in linear orders, 
metabolites are random combinations of some basic elements (e.g. C, H, O, S, N, and 
P). Moreover, the chemical and physical diversities of metabolites make them difficult 
to be identifed based on MS non-targeted approach. In Chapter 2, 4, 5 and 6, we 
examined metabolic fingerprints obtained by LC-MS untargeted methods and found 
numerous metabolic features which have shown to be altered significantly between 
sample cohorts. While we were able to annotate some of them, they need to undergo 
strict experimental verification procedures. Authentic standards need to be obtained 
and analysed under the identical experimental conditions with the biological samples. 
For identification with high confidence level, mass to charge ratio, retention time and 
fragmentation spectra between the samples and the authentic standards need to be 
compared. 
Identification of metabolites associated with liver related diseases would also allow us to 
carry out a secondary analysis, such as enrichment analysis and metabolite mapping, 
enabling further analysis of metabolomics data. Enrichment analysis computes 
metabolic pathways that have been significantly altered by using a collection of pre-
defined metabolite pathways and disease states obtained from the literature. This 
analysis can aid identification and interpretation of patterns on metabolite 
concentration/level changes in a biologically meaningful context. Meanwhile, 
Metabolite mapping provides a visual representation of metabolomics data by 




obtained from a biochemical database. Therefore, achieving identification of interest 
metabolites would allow these secondary analyses to be carried out, in turn providing 
good biological interpretations of the data. 
 
7.2.3 Metabolomics analysis standardisation  
Metabolomics-based strategies have become a major part of modern clinical research, 
allowing for a better understanding of pathophysiological conditions and disease 
mechanisms, as well as providing innovative tools for more adequate diagnostic and 
prognosis approaches. Nevertheless, compared to other ‘-omics’ studies, research 
conducted with metabolomics approach lack the standardisation for sampling protocols, 
data exchange and data treatment workflow. Examples of such specifications have been 
proposed by Coordination of Standards in Metabolomics (COSMOS) and The 
Chemical Analysis Working Group of the Metabolomics Standards Initiative (MSI). 
COSMOS develops a robust data frame and exchange standards for metabolomics data 
expediates the transfer of experimental information between research groups, as well as 
potentially to publishers and funders. Also, MSI provides a biological and experimental 
context for the data, enables experimental replication, and facilitates the comparison of 
data by other researchers. Therefore, there is a great need to apply such specifications 
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